Skip to main content
PLOS Biology logoLink to PLOS Biology
. 2023 Dec 4;21(12):e3002416. doi: 10.1371/journal.pbio.3002416

Systematic and scalable genome-wide essentiality mapping to identify nonessential genes in phages

Denish Piya 1, Nicholas Nolan 2, Madeline L Moore 3, Luis A Ramirez Hernandez 3, Brady F Cress 1,4, Ry Young 5, Adam P Arkin 1,2,3,*, Vivek K Mutalik 1,3,*
Editor: Paula Jauregui6
PMCID: PMC10695390  PMID: 38048319

Abstract

Phages are one of the key ecological drivers of microbial community dynamics, function, and evolution. Despite their importance in bacterial ecology and evolutionary processes, phage genes are poorly characterized, hampering their usage in a variety of biotechnological applications. Methods to characterize such genes, even those critical to the phage life cycle, are labor intensive and are generally phage specific. Here, we develop a systematic gene essentiality mapping method scalable to new phage–host combinations that facilitate the identification of nonessential genes. As a proof of concept, we use an arrayed genome-wide CRISPR interference (CRISPRi) assay to map gene essentiality landscape in the canonical coliphages λ and P1. Results from a single panel of CRISPRi probes largely recapitulate the essential gene roster determined from decades of genetic analysis for lambda and provide new insights into essential and nonessential loci in P1. We present evidence of how CRISPRi polarity can lead to false positive gene essentiality assignments and recommend caution towards interpreting CRISPRi data on gene essentiality when applied to less studied phages. Finally, we show that we can engineer phages by inserting DNA barcodes into newly identified inessential regions, which will empower processes of identification, quantification, and tracking of phages in diverse applications.


In this work, authors use an arrayed genome-wide CRISPR interference assay to map gene essentiality landscape in the canonical coliphages λ and P1.

Introduction

Bacteriophages (phages) are the most abundant biological entities on earth and are postulated to play a crucial role in environmental nutrient cycles, agricultural productivity, and human health [1,2]. The full scope of the roles phages play in regulating the activity and adaptation of microbial communities is still emerging [35]. Phages represent one of the largest pools of genetic diversity with unexplored functional information [69]. For example, the majority of phage genes (>70% to 80%) identified by bioinformatic analysis are of unknown function and show no sequence similarity to characterized genes [10]. Homology-based approaches to connect phage genes to their function are limited by the lack of experimental data [11,12]. While focused biochemical and genetic analysis are the gold standard for assessment of gene functions, most of these methods are not scalable to the vast amount of new genes being discovered [10]. Unless we develop methods to fill the knowledge gap between phage genetic diversity and gene function, we will be seriously constrained in understanding the mechanistic ecology of phages in diverse microbiomes and harness them as engineerable antimicrobials and microbial community editors [13,14].

Gaps in phage gene-function knowledge exist even for some of the most well-studied canonical phages [15,16]. Nevertheless, the application of classical phage genetic tools to a few canonical phages over the last few decades has paved the way for generating foundational knowledge of the phage life cycle [15,17,18]. A number of recent technological innovations have also addressed the growing knowledge gap between phage-gene-sequence and the encoded function [1921]. These innovations range from classical recombineering methods [22,23] and new phage engineering platforms [2428] to genome editing tools such as CRISPR systems, with or without recombineering technology to create individual phage mutants [13,25,2933]. Importantly, no method for assessing essentiality without genome modification has been reported. As such, the field is in need of genome-wide technologies that can be used rapidly across diverse phages to assess gene function [14]. At minimum, such a method would provide the foundational knowledge of which phage genes are essential for its infection cycle in a given host, a prerequisite for understanding host range and for engineering.

Catalytically inactive CRISPR RNA (crRNA)-directed CRISPR endonucleases or CRISPR interference (CRISPRi) technology has emerged as a facile tool for carrying out genome-scale targeted interrogation of gene function in prokaryotic and eukaryotic cells without modification of the genome [34,35]. A catalytically inactive or “dead” Cas protein (such as dCas9 or dCas12a) enables programmable transcriptional knockdown (by binding to DNA and forming a transcriptional road block) yielding a loss-of-function phenotype in a DNA sequence–dependent manner [3641]. While CRISPRi was first developed using dCas9, alternative Cas variants like dCas12a have achieved efficient knockdown in diverse bacteria [4244]. Both dCas9 and dCas12a are similarly effective for CRISPRi in many circumstances; however, advantages of dCas12 include more efficient restriction of a covalently modified phage genome (for example, T4 phage [45]) and simpler cloning of dual crRNAs on short oligos relative to longer dCas9 single-guide RNAs. Recent work demonstrated that dCas12a is capable of inhibiting infection by phage λ when targeting the essential gene cro, suggesting that application of dCas12a with arrayed crRNAs might facilitate genome-wide fitness measurements in phages [46]. The ability to effectively block transcription at target sites distant from promoters makes dCas12a potentially well suited for repressing transcription of phage genes within operons that show overlapping genetic architecture [15,17,18,47,48] and those that are highly regulated or vary in expression levels [4951] in a noncompetitive plaque assay.

Here, we adopted catalytically inactive Cas12a (dCas12a) to carry out systematic genome-wide interference assays in 2 canonical phages. The first is coliphage lambda, arguably the best characterized virus in terms of individual gene function and developmental pathways [17]. The second is coliphage P1, which, as a powerful generalized transducing phage, was instrumental in the development of Escherichia coli as a primary genetic model [52]. Its genome is also well annotated but less experimentally characterized than lambda. We first benchmark the CRISPRi technology by applying it to a known set of essential and nonessential genes in both phages (lytic variants, λcI857, and P1vir, here onwards as lambda or λ and P1, respectively) and then extend it genome-wide to query essentiality of all genes in both phages. Although some ambiguities are revealed and significant polarity effects are detected, the method is clearly demonstrated to be applicable to the rapid assignment of nonessential loci in phages, thus paving the way for systematic genome-scale engineering in a variety of applications.

Results

Setting up CRISPRi assay targeting phage genes

To ascertain that dCas12a can repress phage gene expression, we designed a phage targeting CRISPRi plasmid system following earlier work [53] by expressing both dCas12a and a crRNA to target specific genes (Methods). Briefly, we placed dCas12a under an anhydrotetracycline (aTc)-inducible Tet promoter and the CRISPR array including the phage targeting crRNA under a strong constitutive promoter on a medium copy plasmid. We then selected a set of known essential and nonessential genes that encode proteins needed at different copy numbers for lambda and P1 (Fig 1). For lambda, we chose E, which encodes the major capsid protein, and Nu1, which encodes the small terminase subunit. For P1, we chose genes 23, pacA, and sit, encoding the major capsid protein, large terminase subunit, and tape measure protein, respectively [17,52]. In addition to these essential phage genes, we also chose nonessential P1 genes such as ppp, upfB, or ddrB [54]. We identified Cas12a protospacer adjacent motif (PAM) sites (TTTV) in the 5′ end of the genes (approximately 20% downstream of the start site) and used 28 bp nucleotide sequence immediately downstream of the PAM site in the coding strand as the spacer region for designing crRNAs.

Fig 1. Design and testing of CRISPRi knockdowns to assess gene essentiality in phages lambda and P1.

Fig 1

(a) Schematic of CRISPRi assay system. (b) Representative images of plaque assays to validate the dCas12a CRISPRi system using gene targets with known essentiality. We employed crRNAs targeting 2 essential genes of phage λ: genes encoding major capsid protein (E) or DNA packaging subunit (Nu1). For phage P1, we used crRNA targeting 3 essential genes: encoding the major capsid protein (gene 23 encoding Mcp), DNA packaging subunit (PacA), and tape measure protein (Sit); and 3 nonessential genes: ppp, upfB, or ddrB. For comparison, phage plaques appearing on an E. coli BW25113 lawn expressing a nontargeting crRNA as a control are shown for both phages (Ctrl).

We performed plate-based CRISPRi efficiency assays by moving each variant of the CRISPRi plasmid into E. coli BW25113 separately and induced the expression of dCas12a before plating serial dilution of the 2 phages (Methods). After overnight incubation, we compared the plating efficiency on lawns expressing the gene-targeting crRNAs versus a control lawn in which the crRNA did not target either phage (Fig 1B). We observed that induction of CRISPRi targeting essential genes E and nu1 of lambda and mcp, pacA, and sit of P1 all showed severe compromise in phage growth (measured as plaque formation), whereas targeting nonessential genes ppp, upfB, or ddrB of P1 did not. Overall, our CRISPRi benchmarking assays indicated that the dCas12a CRISPRi platform can be used to assess essentiality of phage genes expressed at different levels during the infection cycle.

Genome-wide CRISPRi to map gene essentiality in λ

To extend our initial observations to systematically query gene essentiality at genome-wide levels, we considered λ as our pilot case, since it is the most deeply characterized phage with detailed assessments of gene functions well represented in the literature [17,55]. Decades of work on suppressible nonsense mutants of λ phage have helped to define 28 genes (out of total 73 open reading frames (ORFs)) as essential for phage growth (Table 1) providing a well-characterized test bed for validation of our genome-wide CRISPRi assay.

Table 1. Gene essentiality mapping of phage lambda genome.

Locus_tag Gene function/Protein name [17] EOP_average S.D. This work Literature
lambdap01 nu1 DNA packaging protein 5.5E-06 2.1E-06 E E [91]
lambdap02 A TerL 1.3E-06 4.7E-07 E E [92,93]
lambdap03 W gpW family protein 3.0E-05 1.4E-05 E E [93,94]
lambdap04 B portal 2.5E-05 2.1E-05 E E [92,93]
lambdap05 C S49 family peptidase/capsid component; Viral protease <2.0E-7 E E [93,95]
lambdap06 nu3 scaffolding protein <2.0E-7 E E [93,96]
lambdap07 D head decoration protein 6.8E-06 2.4E-07 E E [93,97]
lambdap08 E major capsid protein <6.4E-6 E E [93,97]
lambdap09 Fi DNA packaging protein FI 2.0E-05 0.0E+00 E E [93,98]
lambdap10 Fii head-tail joining protein <2.0E-7 E E [94]
lambdap11 Z tail protein 2.5E-05 7.1E-06 E E [55]
lambdap12 U tail protein 3.5E-05 2.1E-05 E E [55]
lambdap13 V tail protein 1.7E-05 1.9E-05 E E [55]
lambdap14 G minor tail protein G <6.4E-6 E E [99]
lambdap15 T tail assembly protein T 1.2E-05 1.2E-05 E E [99]
lambdap16 H tail tape measure protein 1.0E-06 9.4E-07 E E [99]
lambdap17 M tail protein <2.0E-7 E E [99]
lambdap18 L minor tail protein L <2.0E-7 E E [99]
lambdap19 K tail protein 8.7E-05 1.2E-04 E E [99]
lambdap20 I tail component 2.6E-05 2.7E-05 E E [100]
lambdap21 J host specificity protein J 1.1E-05 1.2E-05 E E [92]
lambdap26 lom Outer membrane beta-barrel protein Lom 8.8E-01 5.3E-01 NE NE [17]
lambdap27 stf protail fiber N-terminal domain containing protein 3.0E+00 2.8E+00 NE NE [62]
lambdap90 orf206b hypothetical protein 4.3E+00 1.1E+00 NE NE [62]
lambdap28 tfa tail fiber protein 6.3E+00 5.3E+00 NE NE [62]
lambdap29 orf-194 tail fiber assembly protein 3.3E+00 1.1E+00 NE NE [62]
lambdap80 ea47 5.5E+00 6.4E+00 NE NE [17]
lambdap81 ea31 1.2E+00 1.1E+00 NE NE [17]
lambdap82 ea59 ATP-dependent endonuclease 1.3E+01 1.7E+01 NE NE [17]
lambdap33 int tyrosine-type recombinase/integrase 2.8E+00 3.2E+00 NE NE [55]
lambdap34 xis excisionase 1.6E+00 1.1E+00 NE NE [55]
lambdap35 NT
lambdap36 ea8.5 1.4E+00 1.3E+00 NE NE [17]
lambdap83 ea22 ead/Ea22-like family protein 2.2E+00 2.3E+00 NE NE [17]
lambdap37 orf61 hypothetical protein 9.7E-01 8.1E-01 NE NE [17]
lambdap38 orf63 DUF1382 family protein 1.3E+00 3.8E-01 NE NE [17]
lambdap39 orf60a DUF1317 domin-containing protein 2.4E+00 2.0E+00 NE NE [17]
lambdap41 exo YqaJ viral recombinase family protein 6.9E-01 4.4E-01 NE NE [17]
lambdap84 bet recombination protein Bet 2.1E+00 2.5E+00 NE NE [17,101]
lambdap42 gam host-nuclease inhibitor protein Gam 1.4E+00 1.3E+00 NE NE [17,101]
lambdap85 kil host cell division inhibitory peptide Kil 1.0E+00 0.0E+00 NE NE [102]
lambdap86 cIII protease FtsH-inhibitory lysogeny factor CIII 1.1E+00 3.1E-01 NE NE [103,104]
lambdap45 ea10 DUF2528 family protein 1.7E+00 4.7E-01 NE NE [17]
lambdap46 ral Restriction inhibitor protein ral 1.1E+00 3.2E-01 NE NE [60,61]
lambdap47 orf28 hypothetical protein 1.3E+00 4.7E-01 NE NE [17]
lambdap48 sieB Superinfection exclusion protein B 1.5E+00 7.1E-01 NE NE [105]
lambdap49 N antitermination protein N 1.8E-04 1.2E-04 E E [106,107]
lambdap53 rexB exclusion protein 1.4E+00 1.3E+00 NE NE [17,105]
lambdap87 rexA exclusion protein 3.8E+00 4.0E+00 NE NE [17,105]
lambdap88 cI lysogenic repressor 5.3E+00 6.6E+00 NE NE [103,108,109]
lambdap57 cro lytic repressor <7.5E-6 E E [110]
cII NT NE [103,108,109]
lambdap89 O replication protein <7.5E-6 E E [111,112]
lambdap61 P DNA replication protein <7.5E-6 E E [111,112]
lambdap62 ren protein ren 1.20E-02 7.7E-06 E NE [113]
lambdap63 ninB recombination protein NinB 3.00E-05 5.4E-04 E NE [17,65]
lambdap64 ninC phosphoadenosine phosphosulfate reductase family protein clearing on E-1 E NE [17,65]
ninD NT NE [17,65]
ninE NT NE [17,65]
lambdap67 ninF 4.00E-05 4.0E-06 E NE [17,65]
lambdap68 ninG recombination protein NinG 8.0E-06 1.1E-04 E NE
ninH NT NE [17,65,113]
lambdap70 ninI serine/threonine phosphatase 4.0E-06 5.8E-06 E NE [17,65]
lambdap71 Q antitermination protein 1.6E-05 6.1E-06 E E [65]
lambdap73 orf-64 hypothetical protein 1.2E-02 9.1E-02 NE
lambdap74 S holin/anti-holin 1.0E-05 4.6E-05 E E [114]
lambdap92 S’ holin/anti-holin 1.0E-05 1.7E-04 E E [114]
lambdap75 R endolysin 6.0E-02 5.1E-02 NE E [115]
lambdap76 Rz I-spanin 5.0E-04 1.5E-01 E E [116]
Rz1 NT E [116]
lambdap77 bor serum resistance lipoprotein Bor 7.9E-01 3.0E-01 NE NE [17]
lambdap78 - putative envelope protein 1.9E+00 1.3E+00 NE NE [17]
lambdap79 - hypothetical protein 3.0E-04 1.1E-04 E NE [17]
Assay with pQ plasmid
lambdap62 ren protein ren 1.20E-02 1.7E+00 NE NE [113]
lambdap63 ninB recombination protein NinB 3.00E-01 9.1E-01 NE NE [17,65]
lambdap64 ninC 1.00E+00 1.5E+00 NE NE [17,65]
ninD NE [17,65]
ninE NE [17,65]
lambdap67 ninF 0.03 1.4E+00 NE NE [17,65]
lambdap68 ninG recombination protein NinG 0.2 2.1E-01 NE NE
ninH NE [17,65,113]
lambdap70 ninI serine/threonine phosphatase 1 1.5E+00 NE NE [17,65]

E, essential; NE, nonessential; NT, not tested.

We designed individual crRNAs targeting 67 out of 73 genes of the lambda genome, using the same criteria as used for the pilot studies (by locating PAM sites in the 20% to 33% of the way through the CDS region of each gene to account for any possible alternative start sites for genes) (S1 Fig). The remaining 6 genes (cII, ninD, ninE, ninH, Rz1, and lambdap35) were not tested here due to lack of canonical PAM sites. The designed crRNAs were synthesized as separate pairs of oligos and cloned into the CRISPRi plasmid system downstream of a strong constitutive promoter (Methods). Each of these plasmids encoding crRNAs were arranged in an arrayed format and moved into E. coli BW25113 as indicator strains for the plate-based CRISPRi assay to measure the efficiency of plating (EOP) (Fig 2, described above, and Methods). The EOP is a quantitative measure of the knockdown for each guide RNA. We assessed the reproducibility of EOP estimations by carrying out biological replicates (total assays >150) and depicted the average EOP of every gene on the lambda map (Fig 3 and Table 1, Note A in S1 Text).

Fig 2. Genome-wide CRISPRi design and assay format.

Fig 2

Schematic of steps involved in the arrayed CRISPRi knockdown experiments to assess gene essentiality in phage infectivity cycle. Created with BioRender.com

Fig 3. Gene essentiality landscape of phage λ.

Fig 3

The genome-wide map of gene essentiality is shown by calculating the EOP as the ratio of plaques appearing on E. coli BW25113 lawn expressing crRNA targeting respective lambda phage genes to plaques appearing on BW25113 lawn expressing a nontargeting crRNA. The EOP estimations were done by carrying out biological replicates and depicted the average EOP of every gene on the lambda phage genome map (Methods). Transcripts mentioned in the main text (with promoters) are indicated as thick horizontal arrows: orange, immediate-early transcripts; purple, early transcripts; and red, late transcripts. The underlying data for this figure can be found in Table 1 and S1 Data.

In total, our CRISPRi assays indicated 35 genes as essential and 32 genes as nonessential. For example, consistent with the literature [17], knockdown of genes that encode factors involved in the structural assembly of λ virions, either the capsid morphogenesis (Nu1, A, B, C, Nu3, D, E, FI) or tail morphogenesis (V, G, G-T, H, M, L, K, I, J), were detrimental to phage growth with 5-log reduction in EOP. Similarly, repression of genes encoding crucial factors involved in the lytic phase of lambda phage growth cycle, such as transcription antiterminators (proteins N and Q), DNA replication (proteins O and P), transcriptional regulator (Cro), and programmed disruption of host membrane (holin/antiholin S and S’) all showed approximately 4- to 5-log reduction in EOP, indicating their important role in phage fitness phenotype (Table 1).

The longest stretch of dispensable DNA for lambda encompasses >30% of its genome and is made up of 4 clusters of genes arranged between gene J and gene N (Fig 3). These include a cluster of genes lom-stf-tfa, 20 genes within pL operon, genes in the immunity region (rex and cI genes), and genes encoding the lysis program (R and Rz). We found, except for gene N, all genes within pL operon are dispensable for lambda plaque formation (Fig 3 and Table 1). Some of these genes provide functions that would not be expected to have a plaque-formation defect on fully competent lawns, like the superinfection exclusion genes (rexA, rexB, sieB) [56] and genes involved in lysogeny (int, xis, CIII) [57], but others might, such as homologous recombination (exo, bet, gam) [58] and inhibition of host cell division (kil) [59]. The knockdown of ral (encoding a restriction inhibitor protein) does not result in a major defect in the EOP because our indicator strain lacks a functional type I restriction system [60,61]. To probe the essentiality of ral, we repeated the knockdown assays on 2 different strains with active type I restriction system (Methods). These assays indicate the conditional essentiality of ral that depends on the genotype of the target bacterial strain (S2 Fig). The dispensability of the side tail fiber (which requires stf and tfa) is in agreement with the known frameshift mutation in the stf locus in laboratory strains of λ [62]

Interestingly, the CRISPRi-mediated knockdown of a cluster of delayed early genes (ren, ninB/C/F/G/I) in the PR transcriptional unit indicated that all were essential for plaque-formation, contradicting well-established literature [17,6365]. This “nin region” lies between the essential DNA replication genes O and P and the Q gene, encoding the essential late transcription antiterminator. It is known that phages with a deletion of all the nin genes retain full plaque-forming ability [6365]. The simplest interpretation for this discrepancy is that knockdowns in the nin region are polar on transcription of gene Q, the last gene in the transcriptional unit. Polarity has been previously observed for CRISPRi knockdowns in a bacterial context, resulting in false positives in gene function assignments [6670]. In lambda phage, all genes past cro are subject to N-mediated antitermination [17,71], and to our knowledge, CRISPRi knockdowns and polarity effects have not been tested with phage encoded antitermination systems. To determine whether the essential phenotype of the nin region genes in our assays is due to polarity on gene Q, we repeated the knockdown assays on an indicator strain that provides Q in trans from an inducible plasmid [72]. In these conditions, all 5 genes in the nin region targeted by CRISPRi were found to be nonessential, whereas providing Q had no effect on the essentiality of O and P (Figs 3 and S3). These results also conclude that dCas12a-mediated CRISPRi knockdown repression is insensitive to N-mediated antitermination. The Q protein is also an antiterminator and is required for expression of the 27 genes of the late transcript [17,71]. Although most of the genes of this transcript are known to be essential and score that way in our knockdown assays, two of the most promoter-proximal genes score as nonessential, including lambda orf64 and, to a partial degree, R, which shows an intermediate plaque-forming defect. While R encodes the endolysin required for lysis, it is known to be produced in great excess, so a significant knockdown might still generate enough bacteriolytic activity to account for the intermediate plaque defect. Orf64 is indicated to be nonessential [17], but it is unclear why the knockdown is not polar on the many essential genes downstream.

Extending genome-wide CRISPRi assay to coliphage P1

We next extended the genome-wide CRISPRi knockdown assays to assess gene essentiality in coliphage P1. The 93-Kbp genome of P1 is composed of 117 genes, organized into 45 transcriptional units, with 8 involved in the lysis-lysogeny switch and plasmid prophage maintenance, while 37 are involved in lytic development [52]. Despite its paradigm status, a large proportion of gene function assignments still awaits experimental verification [52,73]. Early gene expression and the lytic-lysogenic decision are controlled by the primary phage repressor C1, while Lpa (Late Promoter Activator) positively regulates late transcription. There are 11 late promoters, all of which have a conserved 9 bp inverted repeat that serves as the Lpa-binding site. Compared to lambda, there is no direct experimental evidence of a protein playing a role of antitermination in P1. Nevertheless, there are strong indications that P1 does encode antiterminators [52,74]. Among the 117 genes, 30 have been identified as essential for plaque formation by amber mutant and targeted deletion methods (Table 2 and Notes B in S1 Text). Experimental evidence for nonessentiality is available for 55 other genes, which makes P1 nearly as good for benchmarking the CRISPR knockdown strategy as lambda.

Table 2. Gene essentiality mapping of Phage P1 genome.


locus_tag
gene
function[52]

EOP_average

SD
This
work

Literature
P1_gp002 cra cre associated function 6.6E-01 1.3E-01 NE NE[117,118]
P1_gp003 cre cyclization recombinase 1.2E+00 8.1E-01 NE NE[117,118]
P1_gp004 c8 establishment of lysogeny 1.5E+00 3.9E-01 NE
P1_gp005 ref recombination enhancement 1.3E+00 3.5E-01 NE NE[118]
P1_gp006 mat maturation control 2.8E-01 3.5E-03 NE E[119]
P1_gp007 res restriction component 1.2E+00 3.5E-02 NE NE[120]
P1_gp008 mod modification component 1.0E+00 3.2E-01 NE NE[120]
P1_gp009 lxc modulator of C1 action; 7.0E-01 4.2E-01 NE NE[121]
P1_gp010 ulx enhances incorporation of darB 6.4E-01 1.6E-01 NE NE[122]
P1_gp011 darB antirestriction 5.8E-01 2.5E-01 NE NE[122]
P1_gp012 prt portal <3.4E-6 E E[52]
P1_gp013 pro head processing <3.4E-6 E E[52]
P1_gp115 lydE putative antiholin 9.8E-01 8.8E-01 NE
P1_gp014 lydD putative holin 1.1E+00 1.0E-01 NE
P1_gp015 lyz lysozyme 5.0E-02 3.5E-03 E E[123]
P1_gp016 ssb single stranded DNA binding protein 5.7E-01 2.0E-02 NE
P1_gp017 isaA IS1 insertion-associated gene 8.6E-01 4.7E-01 NE
P1_gp018 insB IS1 transposition protein 5.1E-01 1.6E-01 NE
P1_gp019 insA IS1 transposition protein 1.0E+00 2.2E-01 NE
P1_gp020 isaB IS1 insertion-associated gene 1.4E+00 2.2E-01 NE
P1_gp021 hxr possible repressor; homolog of Xre 1.6E+00 1.2E+00 NE NE[122]
P1_gp022 ddrB antirestriction 8.5E-01 1.3E-01 NE NE[122]
P1_gp116 iddB internal to ddrB 5.4E-01 2.6E-01 NE NE[122]
P1_gp023 ddrA antirestriction 9.8E-01 3.1E-01 NE NE[122]
P1_gp024 darA antirestriction 6.5E-01 2.9E-01 NE NE[122]
P1_gp025 hdf antirestriction 1.2E+00 8.4E-01 NE NE[122]
P1_gp026 lydB lysis determinant;
prevents premature lysis
2.3E-02 2.6E-02 E NE[123,124]
P1_gp027 lydA holin 1.2E-01 2.4E-03 NE NE[123,124]
P1_gp028 lydC holin 1.1E+00 1.2E-01 NE
P1_gp029 cin site-specific recombinase 1.4E+00 9.5E-01 NE NE[125]
P1_gp001 Sv prime C-terminal moiety of tail fiber gpS 5.3E-01 3.2E-01 NE NE [126]
P1_gp030 U prime structural protein gpU
prime of tail fiber
8.6E-01 8.0E-01 NE NE [126]
P1_gp031 U tail fiber structure or assembly <5.2E-5 E
P1_gp032 S tail fiber structure or assembly <5.2E-5 E
P1_gp033 R tail fiber structure or assembly <5.2E-5 E E[127]
P1_gp034 16 baseplate or tail tube <5.2E-5 E E[128]
P1_gp035 bplA putative baseplate structure, may correspond to gene 3 <2.9E-5 E
P1_gp036 pmgA Putative morphogenetic function <2.9E-5 E E[73]
P1_gp037 sit putative tape measure protein <2.9E-5 E
P1_gp038 pmgB Putative morphogenetic function <2.9E-5 E E[73]
P1_gp039 tub tail tube <2.9E-5 E
P1_gp040 pmgC Putative morphogenetic function <2.9E-5 E E[73]
P1_gp041 simC superimmunity 1.7E+00 6.9E-01 NE NE[129]
P1_gp042 simB superimmunity 3.8E+00 8.4E-01 NE NE[129]
P1_gp043 simA superimmunity 9.0E-01 4.9E-01 NE NE[129]
P1_gr044 c4 RNA acts on icd and ant mRNA 8.3E-01 9.4E-01 NE
P1_gp045 icd reversible inhibition of cell division 6.0E-01 2.2E-01 NE NE[130]
P1_gp046 ant1 antagonizes C1 represssion1 2.0E+00 1.1E+00 NE NE[131]
P1_gp047 ant2 product antagonizes C1 2.3E+00 1.8E+00 NE NE[131]
P1_gp048 ask regulatory region of kilA gene; 1.2E+00 4.9E-01 NE
P1_gp049 kilA product can kill host 8.6E-01 8.0E-01 NE NE[131]
P1_gp050 repL initiates replication at oriL 7.1E-01 3.0E-01 NE NE[131]
P1_gp051 rlfA possibly associated with
lytic replication
1.3E+00 6.1E-02 NE
P1_gp052 rlfB possibly associated with
lytic replication
8.8E-01 3.0E-02 NE
P1_gp053 pmgF putative morphogenetic function 1.2E+00 1.0E-02 NE NE[73]
P1_gp054 bplB baseplate structure <1.2E-7 E
P1_gp055 pmgG putative morphogenetic function <1.2E-7 E E[73]
P1_gp056 21 baseplate or tail tube <1.2E-7 E * [128]
P1_gp057 22 tail sheath <1.2E-7 E * [128]
P1_gp058 23 Major head protein <1.2E-7 E * [128]
P1_gp059 parB active partitioning of P1 plasmid
during cell division
1.3E+00 7.6E-01 NE
P1_gp060 parA active partitioning of P1 plasmid
during cell division
1.6E+00 1.5E+00 NE
P1_gp061 repA initiates replication from oriR;
plasmid replication
9.5E-01 6.4E-02 NE
P1_gp062 upfA 1.2E+00 8.9E-01 NE NE[73]
P1_gp063 mlp membrane lipoprotein precursor 2.4E-01 1.9E-01 NE
P1_gp064 ppfA possible periplasmic function 1.3E+00 1.2E+00 NE
P1_gp065 upfB 1.3E+00 1.0E+00 NE NE[73]
P1_gp066 upfC 1.1E+00 6.8E-01 NE NE[73]
P1_gp067 uhr 8.6E-01 1.9E-01 NE NE[73]
P1_gp068 hrdC hpothetical recombination
associated protein of RdgC family
8.7E-01 4.6E-01 NE
P1_gp069 dmt-B DNA methlytransferases;
methlysates A at GATC
1.4E+00 1.2E+00 NE NE[132]
P1_gp070 dmt-A 1.4E+00 7.6E-03 NE
P1_gt071 trnT 9.2E-01 4.0E-01 NE
P1_gp072 plp putative lipoprotein 1.6E+00 8.2E-01 NE
P1_gp073 upl 1.9E+00 5.9E-01 NE NE[73]
P1_gp074 tciA tellurite or colicin resistance or inhibition of cell division 6.5E-01 6.5E-02 NE
P1_gp075 tciB tellurite or colicin resistance or inhibition of cell division 9.9E-01 1.0E-01 NE
P1_gp076 tciC tellurite or colicin resistance or inhibition of cell division 1.3E+00 4.4E-01 NE
P1_gt117 trnI 1.4E+00 7.9E-01 NE
P1_gp077 ban dnaB homolog 1.2E+00 4.8E-01 NE NE[133]
P1_gp078 dbn downstream of ban 1.3E+00 1.3E-01 NE NE[73]
P1_gp079 5 baseplate <2.1E-6 E
* [128]
P1_gp080 6 tail length 8.3E-03 1.3E-03 E * [128]
P1_gp081 24 baseplate or tail stability 4.9E-03 5.0E-03 E * [128]
P1_gp082 7 tail stability <8.2E-6 E * [128]
P1_gp083 25 tail stability 1.1E-01 6.6E-02 NE * [128]
P1_gp084 26 baseplate; 1.2E-01 1.5E-01 NE * [128]
P1_gp085 pmgL putative morphogenetic function 1.3E+00 9.4E-01 NE NE[73]
P1_gp086 pmgM putative morphogenetic function 3.8E-01 2.1E-01 NE NE[73]
P1_gp087 pmgN putative morphogenetic function 1.4E-02 1.5E-03 E NE[73]
P1_gp088 pmgO putative morphogenetic function 1.1E+00 8.7E-01 NE NE[73]
P1_gp089 pmgP putative morphogenetic function 7.2E-01 7.3E-02 NE NE[73]
P1_gp090 ppp protein phosphatase 1.2E+00 8.0E-02 NE NE[73]
P1_gp091 pmgQ putative morphogenetic function 1.4E+00 7.5E-01 NE NE[73]
P1_gp092 pmgR putative morphogenetic function 9.4E-01 3.0E-01 NE E[73]
P1_gp093 pmgS putative morphogenetic function 1.2E+00 3.2E-01 NE NE[73]
P1_gp094 pap acid phosphatase 7.7E-01 2.3E-01 NE NE[73]
P1_gp095 pmgT putative morphogenetic function 9.8E-01 9.7E-01 NE NE[73]
P1_gp096 pmgU putative morphogenetic function 2.1E-01 6.4E-02 NE NE[73]
P1_gp097 pmgV putative morphogenetic function 1.9E+00 2.0E+00 NE NE[73]
P1_gp098 upfM unknown protein function NT NE[73]
P1_gp099 upfN unknown protein function 8.3E-01 2.4E-01 NE NE[73]
P1_gp100 upfO unknown protein function 9.5E-01 6.4E-01 NE NE[73]
P1_gp101 hot DNA replication 1.2E+00 1.6E+00 NE
P1_gp102 lxr LexA-regulated functions 7.9E-01 7.7E-01 NE
P1_gp103 humD DNA repair 5.4E-01 3.3E-01 NE
P1_gp104 phd anti-toxin of P1 toxin-antitoxin system 5.5E-01 7.1E-02 NE
P1_gp105 doc toxin of P1 toxin-antitoxin system 3.6E-01 1.2E-02 NE
P1_gp106 pdcA unknown protein function NT NE[73]
P1_gp107 pdcB unknown function 6.8E-01 2.6E-01 NE NE[73]
P1_gp108 lpa late promoter activator <1.2E-7 E * [134]
P1_gp109 pacA DNA packaging <1.2E-7 E * [135]
P1_gp110 pacB DNA packaging <1.2E-7 E * [135]
P1_gp111 c1 lytic repressor 1.4E+00 1.3E+00 NE
P1_gp112 coi C1 inactivator 7.4E-01 8.4E-01 NE NE[136]
P1_gp113 imcB immunity function 8.2E-01 7.3E-01 NE
P1_gp114 imcA immunity function NT

E, essential; NE, nonessential; NT, not tested.

* amber mutant reported

We designed individual crRNAs targeting 114 out of the 117 genes similar to lambda phage (above); the remaining 3 genes (upfM, pdcA, and imcA) were not tested due to lack of PAM sites. Using the same workflow described for lambda, we found 87 genes as nonessential and 27 genes as essential (Figs 4 and S4). Five known essential genes were missed by the knockdown screen: mat, repL, 25, 26, and pmgR. In addition, one gene, pmgN, was found to be essential, in contradiction with the recent deletion analysis survey [73]. From the perspective of identifying nonessential genes, 54 of the 55 genes for which there was some evidence of nonessential character were confirmed by the knockdown. In addition, the knockdown approach demonstrates nonessentiality for a further 33 genes. Taken together, 4 large segments comprising nearly 60 kb of the P1 genome are occupied by genes dispensable for lytic growth and thus available for specific engineering (Table 2).

Fig 4. Gene essentiality landscape of phage P1.

Fig 4

The genome-wide map of gene essentiality is shown by calculating the EOP as the ratio of plaques appearing on E. coli BW25113 lawn expressing crRNA targeting respective P1 phage genes to plaques appearing on BW25113 lawn expressing a nontargeting crRNA. The EOP estimations were done by carrying out biological replicates and depicted the average EOP of every gene on the P1 phage genome map (Methods). The underlying data for this figure can be found in Table 2 and S1 Data.

Downstream application of gene essentiality mapping

To demonstrate one downstream application of the knockdown approach to gene essentiality mapping, we sought to insert a unique DNA tag into both λ and P1 at a gene locus that we found to be dispensable. As DNA barcodes are heritable, they can be used for rapid identification of different phage samples by standardizing the workflow, assuming their insertion does not impact phage fitness. Such unique barcoding of different phages could enable quantitative tracking and measure of individual phage fitness in multiphage formulations in different applications.

As a proof of concept, we inserted a unique DNA barcode in genes res and red, of P1 and lambda, respectively. We used a homologous recombination approach followed by nuclease active Cas12a-based counter selection for barcoded phages in a 2-step process (Methods). Successful DNA barcode insertions into phage genomes were then confirmed by Sanger sequencing of the insertion locus. With these 2 bc (barcoded) constructs, we tested whether we could quantify different phage combinations. To do this, we mixed phage P1-bc and λ-bc in different ratios, incubated at room temperature for 30 minutes, and subjected them to Barseq PCR sequencing [75,76]. Our Barseq quantification method not only successfully quantified different ratios of barcoded phage P1 and lambda but also captured the differences in plaque-forming units/ml of individual phages to barcode abundance (Fig 5).

Fig 5. Insertion and quantification of random DNA barcodes on a nonessential genomic location of lambda and P1vir phage.

Fig 5

(a) Schematic of phage engineering approach: Homologous recombination method was used to engineer phages with random barcodes at a nonessential genomic loci, and nuclease active Cas12a-based counterselection was used to enrich engineered phages. Schematic is shown for barcode insertion and counterselection for lambda phage at the red locus and P1 phage at res locus. Created with BioRender.com. (b) Barcode abundance of P1 phage against its PFU/ml estimations in triplicates. (c) Barcode abundance for both barcoded lambda and P1 phages, when mixed at different ratios. Estimations done in triplicates in a pool (Methods). The underlying data for this figure can be found in S1 Data.

Discussion

CRISPR-based technologies have revolutionized the functional genomics field [34]. CRISPRi, in particular, has emerged as a major technology for genome-wide mapping of essential and nonessential genes in bacteria [34,35]. Here, we assessed the feasibility of using dCas12a system for performing a genome-wide survey of 2 paradigm phages, lambda and P1, using crRNAs designed to achieve gene-specific “knockdown.” Results from our arrayed CRISPRi assays are consistent with known assignments of gene essentiality in both phages, provide novel insights, and present a genome-wide landscape of gene essentiality for phage P1 for the first time, to the best of our knowledge (Tables 1 and 2 and Figs 3 and 4). Lambda and P1 phages have quite distinct transcriptional organization, making CRISPRi differentially suited for probing stretches of nonessential genes in these phages (below). With an organized map of gene essentiality in hand, it is now possible to identify locations in these phage genomes wherein insertion of an exogenous “payload” are less likely to disrupt critical function, as well as longer regions that can be deleted or replaced with custom DNA. As a proof of principle, we demonstrate this by inserting a DNA barcode into the lambda and P1 genome at an inessential loci that provides the ability to track and quantify distinct phages in a mixed phage formulation. Finally, this study uncovers the polar effect of CRISPRi in phages. We recommend using CRISPRi for mapping nonessential regions while caution towards interpreting essential gene assignments when applied to less studied phages where transcripts have not yet been mapped. We discuss these insights below.

Overall, the genome-wide CRISPRi assay results demonstrated dCas12a was effective; that is, nearly every nonessential lambda gene knockdown was scored correctly, and essential lambda genes were scored as essential, based on reduction of plating efficiency by 3 powers of 10 or more in the presence of dCas12a and the cognate crRNA (Fig 3 and Table 1). However, a cluster of delayed early genes in the nin region of the PR transcript of lambda were scored as essential despite unambiguous evidence that this entire region can be deleted without impairing the plaque-forming ability of the phage [6365]. Because of its DNA-binding function, the bound dCas12a/crRNA complex is necessarily a roadblock that would be polar on all downstream genes, as confirmed experimentally for the knockdowns of lacZ in the lacZYA operon of E. coli [38]. The reason for this polarity is because this cluster of nonessential nin genes is upstream of gene Q, which encodes the late-gene activator required for late-gene expression. Thus, roadblocks in the nin genes should be polar on gene Q. Accordingly, when we supplied Q in trans, the nin genes all scored properly as nonessential (Fig 3). Unfortunately, the same rationale applies to the other genes served by PR (Fig 3). Thus, knockdowns in cro, O, and P are also polar on Q. With Q added in trans, all 3 upstream genes read out as essential but only the gene P result is confirming, since the cro and O knockdowns should be polar on essential gene P. The situation is better for the PL transcriptional unit because the only essential gene is the first one, N. Thus, for PL, all 19 genes that were tested are scored correctly, as nonessential.

Similar challenges for CRISPRi essentiality determination are noted for the late genes, expressed from PR’ in a 27-kb mRNA (Fig 3). Twenty-one genes from nu1 through J read out correctly as essential, but since the first 20 knockdowns should be polar on J, nothing can be concluded for their essentiality based on CRISPRi results. Moreover, the results for the upstream genes orf64 and R are confounding. From the same perspective as used on the PR transcript, knockdown roadblocks in all the upstream genes in this transcriptional unit should be read out as essential. This was observed for gene p79 (which is nonessential, but essential in our assay), but it was not observed for the knockdowns of orf64 and R. In CRISPRi studies on bacterial genomes [6670,77], similar polarity issues have been noted, and contradictions have been explained by invoking the presence of cryptic promoters downstream of the roadblock site [69]. For a phage like lambda, where transcriptional organization has been unambiguously established by rigorous genetics and molecular approaches (though new technologies are providing new information [78]), these arguments may not hold. The simplest possibility is that there are large variations in the effectiveness of each roadblock [79], despite the perfect match of 28 nucleotides in each crRNA and, in each case, a TTTV PAM sequence. Hence, in the absence of data assessing the level of readthrough in the orf64 and R roadblocks, useful interpretation of the PR’ results is not practical. An intriguing possibility is that Q-mediated antitermination may play a role in readthrough of these CRISPRi roadblocks. It is widely unappreciated that for all the well-studied phages, late gene expression is always under positive control, either by an antiterminator like lambda Q and the PR’ promoter or by a transcription factor like Lpa and the 11 late promoters of P1 [17,52]. It would be interesting to determine quantitatively how such positive control factors affect the efficacy of Cas12a in CRISPR defense and dCas12a in roadblock knockdowns, with an eye towards possible evolutionary interactions. In any case, the results from knockdowns in the 3 major transcripts of lambda show that only N, P, Q, and J can be confidently established as essential genes. Thus, as noted earlier [66], the nature of CRISPRi roadblock polarity means that essentiality can only be assigned for the last required gene on a transcript. The 2 major lessons from our work on lambda are, first, CRISPRi polarity could assign false positive gene essentiality and therefore recommend caution when applied to less studied phages; and, second, CRISPRi based on DNA roadblocks is of limited utility for analysis of phages that, like lambda, feature long polycistronic transcriptional units. However, for the more utilitarian goal of identifying significant swaths of the phage genome that could be considered “nonessential” and thus available for engineering, this approach still has high value. All of the 14-kb PL transcript beyond N, comprising 15 genes, score unambiguously as nonessential.

Among phage genomes, lambda is arguably the best characterized transcriptional system because of its simplicity, with only 3 promoters involved in lytic development. P1 stands in stark contrast, with at least 45 transcriptional units, including 15 monocistronic units, and several genes served by both early and late promoters. In general, similar results were obtained from the genome-wide knockdown approach as with lambda (Fig 4 and Table 2). Of the 31 genes assigned essential character in the extensive P1 literature, all but 5 were detected by the knockdown screen. However, consideration of the transcript structures and gene positions reveals that of the 26 genes that read out as essential, 18 are located upstream of a gene known to be essential, and, thus, the knockdown readout is uninformative. Moreover, as in the case for the promoter-proximal genes in the lambda late transcriptional unit, P1 has a confounding transcript. Genes 25 and 26, which were discovered as amber mutants and thus must be considered as known essentials, both score as nonessential genes in our assays. This constitutes a double contradiction, not only in the failure to detect essential character but also not exhibiting polarity on the cluster of genes downstream (genes 7, 24, 6, and 5) that correctly read out as required cistrons. The simplest notion is that for some reason, neither the 25 nor 26 roadblocks are effective. Quantitative assessment of roadblock readthrough is beyond the scope of this initial validation screen, but it would be useful to determine the level of blockage and readthrough throughout the lambda and P1 libraries (as recently reported for E. coli [79]). This is especially true since the 2 confounding cases (genes orf64 and R in lambda; genes 25 and 26 in P1) are at the 5′ end of a polycistronic transcriptional unit. Unlike other CRISPRi systems, the dCas12a roadblocks are reported to be independent of promoter-proximity, but that lesson has only been addressed within the lacZYA cistron [38], and not for very long transcripts or for transcriptional units under the positive control of an antiterminator.

Because of tightly overlapped and transcriptionally linked genetic elements in phages, such polarity effects may be difficult to overcome using CRISPRi. The catalytically inactive version of recently reported RNA-targeting Cas13 system might solve some of the polarity effect issues associated with DNA-targeting Cas systems by modulating translation of single genes encoded within operons [29,31]. In addition, the absence of PAM requirements for Cas13 targeting and its broad-spectrum phage targeting capability may enable designing multiple crRNA targeting the same genomic locus, to quickly and comprehensively map gene essentiality landscape in diverse phages [29]. Nevertheless, in contrast to classical genetic methods such as recombineering, that require cumbersome cloning of long homology arm pairs followed by plaque screening to identify edited phages that exist at low abundance relative to wild-type, arrayed CRISPRi assay as presented here offers a simpler and economical approach that only requires cloning a set of short crRNA sequences. By using pooled crRNAs, it may be possible to extend the CRISPRi technology to carry out pooled fitness assays and identify phage genes important in the phage life cycle in a single rapid assay. While this manuscript was under review, successful implementation of dCas13 based genome-wide pooled CRISPRi screen was reported for diverse phages [80] and point to a rich future of diverse functional genomics tools to study phage biology.

Even though the gene essentiality mapping results are dependent on the experimental settings and conditions used in the assay systems, they do open up interesting questions and avenues to assess the role of nonessential and accessory genes in phage development and infection pathways [15,17,18]. By adopting high-throughput CRISPRi assays to map phage gene essentiality in different conditions [81], it may be possible to study the role of such conditional gene essentiality in phage infection. Furthermore, the simple multiplexability of dCas12a crRNAs (for example, dual crRNAs targeting 2 genes) could enable rapid, systematic investigation of synthetic lethal phage gene pairs. Extending such studies to non-model, non-dsDNA phages may further provide us with deeper information needed to study genomic architecture and phage engineering applications. Considering that the different CRISPR-based tools have been successfully applied to multitudes of microbial species [34,82] and have been used to engineer diverse phages, we expect CRISPRi technology to serve as a powerful approach to rapidly identify nonessential and accessory genes and pathways in phage infection cycles.

Methods and materials

Bacterial strains and phages

The bacterial strains and phages used in this study are listed in S1 Table. The oligonucleotides used in this study are listed in S2 Table. All enzymes were obtained from New England Biolabs (NEB), and oligonucleotides were received from Integrated DNA Technologies (IDT). Unless noted, all strains were grown in LB supplemented with appropriate antibiotics at 37°C in the Multitron shaker. All bacterial strains were stored at −80°C for long-term storage in 15% sterile glycerol (Sigma). The genotype of E. coli strains used in the assays include BW25113 (K-12 lacI+rrnBT14 Δ(araB–D)567 Δ(rhaD–B)568 ΔlacZ4787(::rrnB-3) hsdR514 rph-1); MG1655 (F- lambda- ilvG- rfb-50 rph-1) and E. coli C3000 (ATCC15597).

E. coli strains were cultured in LB (Lennox) [10 g/L Tryptone, 5 g/L NaCl, 5 g/L yeast extract] or LB agar [LB (Lennox) with 1.5% Bacto agar)] at 37°C. E. coli strains transformed with plasmids were selected in the presence of 100 μg/mL ampicillin (LB Amp) or 30 μg/mL chloramphenicol (LB cam). Phages were plated using 0.5% top agar [10 g/L Tryptone, 10 g/L NaCl, 5 g/L Bacto agar]. Before plating, 5 mM CaCl2 and 5 mM MgSO4 were added to top agar aliquots.

The phages (lytic phages, λcI857 and P1vir) used in this study were prepared by the confluent plate lysis method using LB bottom plates and 0.5% top agar [83]. Phages were harvested in SM buffer (Teknova), filter sterilized, and stored at 4°C. Plaque assays were performed using spot titration method [83].

Design and construction of spacer duplex

Cas12a recognizes TTTV as the PAM site [53]. For each target gene, PAM sites for Cas12a were identified to serve as toe-holds for the crRNAs. As any genes could have an alternative start site, the PAM sites nearby the annotated start codon of the gene were avoided. To avoid end effects, and based on prior experience in bacterial CRISPRi [70], PAM sites were prioritized if they occurred after 20% of the gene length (so that the dCas12a complex would bind to approximately on the 1/5th position of the gene). The 28-bp nucleotide sequences immediately downstream of the PAM site in the coding strand were selected as the protospacer region. The forward oligo was designed by adding sequences “AGAT” to the 5′ region of the protospacer sequence and sequence “G” to the 3′ region of the protospacer sequence to make the ends of oligos Golden Gate cloning compatible. The reverse oligo was designed by reverse complementing the protospacer sequence from the coding strand and adding sequences “GAAAC” to the 5′ end. Custom python scripts (https://github.com/NickNolan/phage-crispri) were designed for identifying the protospacer regions and respective oligonucleotides.

We processed oligonucleotides by carrying out 5′ phosphorylation and annealing of complementary oligonucleotides in a single tube reaction. The published sequences for phages P1 (NCBI Reference Sequence: NC_005856.1) and λ (NCBI Reference Sequence: NC_001416.1) were used as reference sequences to generate oligos. Each 5 μL reaction comprised 0.5 μL each of the forward and reverse oligonucleotide pair (100 μM stock), 0.5 μL of 10× T4 DNA Ligase Reaction Buffer (NEB), 0.5 μL T4 Polynucleotide Kinase (NEB). The reaction was carried out in a thermocycler as follows: 37°C for 30 minutes, 95°C for 5 minutes, followed by gradient decrease of temperature from 95°C to 25°C (0.5°C every 6 seconds for 140 cycles). To make a working stock of the spacer duplex, the reaction mix was diluted to a final volume of 100 μL by adding milliQ water.

Plasmid construction

The plasmid collection used in this study is listed in S3 Table. All plasmid manipulations were performed using standard molecular biology techniques. The plasmid system encoding nuclease active LbCas12a has been described previously [53]. In brief, LbCas12a is cloned under aTc-inducible Tet promoter, whereas the CRISPR arrays are constitutively transcribed from a strong, synthetic promoter proD [53]. For CRISPRi, catalytically deactivated LbCas12a (dLbCas12a) lacking endonuclease activity was generated by the mutating nuclease domain of LbCas12a. For each CRISPRi plasmid, a spacer targeting a specific phage gene was cloned into the CRISPR array using Golden Gate assembly [84]. Each 5 μL of the reaction contained 0.5 μL of ATP (NEB), 0.5 μL DTT (1 mM final concentration), 0.5 μL 10× CutSmart Buffer (NEB), 0.375 μL BbsI (NEB), 0.125 μL T4 Ligase (NEB), 20 fmol CRISPRi plasmid, and 100 fmol spacer duplex (0.2 μL of the working stock of the spacer duplex). The reaction was cycled between 37°C and 20°C for 5 minutes each at each temperature for 30 cycles and heat inactivated at 80°C for 20 minutes. This same method was followed to clone the spacer duplex into the plasmid encoding nuclease active version of LbCas12a.

For inserting a random DNA barcode into a nonessential region of phage (res and cra-darB region in P1 phage while red gene in lambda; S3 Table), a recombination template was constructed on pBAD24 vector backbone [85]. A synthetic dsDNA was obtained from IDT as a gBlock gene fragment that comprised 2 homology arms, each of 100-bp homology to the nonessential region of the phage genome [86]. In between the two 100-bp homology arms, a random 20-bp DNA barcode flanked by 2 primer-binding regions was inserted so that the barcoded phage genome could be assayed by high-throughput DNA barcode sequencing (BarSeq) technology [75]. The gBlock fragment was PCR amplified and cloned into a PCR-amplified pBAD24 backbone using Gibson assembly [87].

The Golden Gate or Gibson assembly mixture was transformed into competent E. coli 5-alpha cells (NEB) following manufacturer’s recommendations and selected by plating on LB in the presence of appropriate antibiotics. Successful insertion into the plasmid backbone was verified by Sanger sequencing (UC Berkeley DNA Sequencing Facility or Elim Biopharmaceuticals). These pBAD24-derived plasmids would serve as recombination templates.

CRISPRi assays for mapping phage gene essentiality

For CRISPRi knockdown assays, each variant of the CRISPRi plasmid was transformed into E. coli str. BW25113 using standard method [88] and selected on independent LB cam plates. An overnight culture of the transformed strain was used to prepare a lawn on LB cam supplemented with 2 nM or 4 nM aTc for induction of the dCas12a. Phages were serially diluted 10-fold, and 2 μL of each dilution was plated on a lawn of bacterial host. The number of plaques was quantified after overnight incubation at 37°C. The EOP was calculated as the ratio of plaques appearing on BW25113 lawn expressing crRNA targeting respective phage genes to plaques appearing on BW25113 lawn expressing nontargeting crRNA. The nontargeting crRNA targets P1 phage gene 23 in lambda CRISPRi assays while it targets lambda phage gene E in P1 CRISPRi assays. The complete compendium of EOP for each CRISPRi knockdown assay for lambda and phage P1 is listed in Tables 1 and 2, respectively.

To assess the essentiality of the Nin region in λcI857, we transformed all nin targeting CRISPRi plasmids into E. coli str. BW25113, carrying a pQ plasmid system [72], and carried out CRISPRi knockdown assays as described above (S3 Fig). The plasmid pQ, a low-copy plasmid carrying Q, encodes the λ late gene activator under control of a lac/ara hybrid promoter, which is inducible with IPTG and arabinose.

To determine the conditional essentiality of ral, we transformed the ral targeting CRISPRi plasmid into E. coli MG1655 and C3000 strains and carried out CRISPRi knockdown assays in the presence of lambda phage as described above. Both E. coli MG1655 and C3000 strains encode an active type I restriction system. The plaque-forming efficiency was compared between E. coli lawn expressing crRNA targeting ral and P genes and with plaques appearing on E. coli lawn expressing nontargeting crRNA.

Engineering DNA barcoded phages

For inserting the DNA barcode into the phage genome, pBAD24-derived plasmid (S3 Table) was transformed into E. coli str. BW25113 using a 1-step transformation method [88]. Phage stock was appropriately diluted and plated on the lawn of the transformed BW25113 host using full-plate titration method [83]. Individual plaques were picked from the lawn, and the insertion of the DNA barcode was verified by PCR amplifying the junction and Sanger sequencing. The phages obtained from each plaque had a mixed population of unmodified and recombinant phage. This mixed population of phages were further enriched by confluent lysis plating method, and the wt phage in each plaque was counterselected by plating the mixture phage on the lawn of BW25113 host expressing nuclease active Cas12a target the nonessential region of the phage [89].

Barseq assays using DNA barcoded phages

To demonstrate the utility of barcoded phages, we mixed uniquely barcoded P1 and lambda phage lysates in different ratios, in triplicates. To benchmark the barcoded phage quantification with a set of internal controls, we spiked 4 uniquely barcoded E. coli genome preparation into each of the Barseq samples. For performing Barseq PCR reactions, we used phage lysates as templates mixed with E. coli genome preparations. BarSeq PCR in a 50-μl total volume consisted of 20 μmol of each primer. We used an equimolar mixture of BarSeq_P2 primers along with new Barseq3_P1 primers as detailed earlier [75,90]. Briefly, the BarSeq_P2 primer contains the tag that is used for demultiplexing by Illumina software, and the new Barseq3_P1 primer contains an additional sequence to verify that it came from the expected sample (as described earlier) [90]. All experiments were done on the same day and sequenced on the same lane. Equal volumes (5 μl) of the individual BarSeq PCRs were pooled, and 50 μl of the pooled PCR product was purified with the DNA Clean and Concentrator kit (Zymo Research). The final BarSeq library was eluted in 40 μl water. The BarSeq libraries were sequenced on Illumina HiSeq4000 instrument with 50 SE runs. We used in-house Barseq PCR processing code for estimating DNA barcodes in samples [75].

Supporting information

S1 Fig. Lambda phage genome CRISPRi oligo designs.

Blue represents genes, red represents primers, and black is the full genome. Outside is on the positive strand, where inside is negative.

(TIF)

S2 Fig. Conditional essentiality of lambda ral in presence of an active type I restriction-modification system encoded by hsdR-hsdM-hsdS genes.

(a) EOP experiments with crRNA targeting ral in E. coli BW25113 (methods). (b) EOP experiments with crRNA targeting ral in E. coli MG1655 that has an active type 1 restriction modification system. (c) EOP experiments with crRNA targeting ral in E. coli C3000 that has an active type 1 restriction modification system. For comparison, phage plaques appearing on E. coli lawn expressing a crRNA targeting essential gene P and nontargeting crRNA (targets P1 phage mcp) as a control are shown for lambda phage (Ctrl).

(TIF)

S3 Fig. CRISPRi of Nin region without and with plasmid expression gene Q: EOP experiments for assessing CRISPRi polarity effect on Nin region.

(A) EOP for CRISPRi assay for each gene shown (each strain with individual CRISPRi plasmid (Methods). (B) EOP experiments in presence of plasmids pQ and CRISPRi targeting each gene in Nin region context. We used the BW25113 strain with a crRNA vector control (DP51, crRNA targets P1 phage mcp) for estimating EOP.

(TIF)

S4 Fig. P1 phage genome, CRISPRi oligo designs.

Blue represents genes, red represents primers, and black is the full genome. Outside is on the positive strand, where inside is negative.

(TIF)

S1 Table. List of bacterial strains and phages.

(XLSX)

S2 Table. List of primers used in this work.

(XLSX)

S3 Table. List of plasmids used in this work.

(XLSX)

S1 Text. Detailed discussion on phage CRISPRi results.

(DOCX)

S1 Data. The underlying data for all figures.

(XLSX)

Acknowledgments

The authors thank Dr. Jennifer Doudna (Innovative Genomics Institute, UC Berkeley) for sharing reagents and guidance. The authors also thank Dr. Benjamin Adler (Innovative Genomics Institute, UC Berkeley) for comments on the early draft of this manuscript.

Abbreviations

aTc

anhydrotetracycline

CRISPRi

CRISPR interference

crRNA

CRISPR RNA

EOP

efficiency of plating

Lpa

Late Promoter Activator

ORF

open reading frame

PAM

protospacer adjacent motif

Data Availability

All relevant data are within the paper and its Supporting Information files. The underlying data for all figures are provided in supporting information file S1 Data. The complete data from phage Barseq experiments are deposited here https://doi.org/10.6084/m9.figshare.22817084.

Funding Statement

This material by ENIGMA- Ecosystems and Networks Integrated with Genes and Molecular Assemblies (http://enigma.lbl.gov), a Science Focus Area Program at Lawrence Berkeley National Laboratory is based upon work supported by the U.S. Department of Energy, Office of Science, Office of Biological & Environmental Research under contract number DE-AC02-05CH11231 (to V.K.M. and A.P.A.). Phage P1 assay part of this research was supported by the U.S. Department of Energy, Office of Science, through the National Virtual Biotechnology Laboratory, a consortium of U.S. Department of Energy national laboratories focused on response to COVID-19, with funding provided by the Coronavirus CARES Act (to V.K.M. and A.P.A.) and the early design part of this project was funded by the Microbiology Program of the Innovative Genomics Institute, Berkeley (to A.P.A, and V.K.M.). R.F.Y acknowledges funding from the National Institute of General Medical Sciences(NIGMS) grant R35GM136396. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Breitbart M, Bonnain C, Malki K, Sawaya NA. Phage puppet masters of the marine microbial realm. Nat Microbiol. 2018;3:754–766. doi: 10.1038/s41564-018-0166-y [DOI] [PubMed] [Google Scholar]
  • 2.Suttle CA. Marine viruses—major players in the global ecosystem. Nat Rev Microbiol. 2007;5:801–812. doi: 10.1038/nrmicro1750 [DOI] [PubMed] [Google Scholar]
  • 3.Koskella B, Hernandez CA, Wheatley RM. Understanding the Impacts of Bacteriophage Viruses: From Laboratory Evolution to Natural Ecosystems. Annu Rev Virol. 2022;9:57–78. doi: 10.1146/annurev-virology-091919-075914 [DOI] [PubMed] [Google Scholar]
  • 4.Chevallereau A, Pons BJ, van Houte S, Westra ER. Interactions between bacterial and phage communities in natural environments. Nat Rev Microbiol. 2022;20:49–62. doi: 10.1038/s41579-021-00602-y [DOI] [PubMed] [Google Scholar]
  • 5.Correa AMS, Howard-Varona C, Coy SR, Buchan A, Sullivan MB, Weitz JS. Revisiting the rules of life for viruses of microorganisms. Nat Rev Microbiol. 2021;19:501–513. doi: 10.1038/s41579-021-00530-x [DOI] [PubMed] [Google Scholar]
  • 6.Roux S, Krupovic M, Daly RA, Borges AL, Nayfach S, Schulz F, et al. Cryptic inoviruses revealed as pervasive in bacteria and archaea across Earth’s biomes. Nat Microbiol. 2019;4:1895–1906. doi: 10.1038/s41564-019-0510-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Dominguez-Huerta G, Zayed AA, Wainaina JM, Guo J, Tian F, Pratama AA, et al. Diversity and ecological footprint of Global Ocean RNA viruses. Science. 2022;376:1202–1208. doi: 10.1126/science.abn6358 [DOI] [PubMed] [Google Scholar]
  • 8.Neri U, Wolf YI, Roux S, Camargo AP, Lee B, Kazlauskas D, et al. Expansion of the global RNA virome reveals diverse clades of bacteriophages. Cell. 2022;185:4023–4037.e18. doi: 10.1016/j.cell.2022.08.023 [DOI] [PubMed] [Google Scholar]
  • 9.Nayfach S, Páez-Espino D, Call L, Low SJ, Sberro H, Ivanova NN, et al. Metagenomic compendium of 189,680 DNA viruses from the human gut microbiome. Nat Microbiol. 2021;6:960–970. doi: 10.1038/s41564-021-00928-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Hatfull GF. Actinobacteriophages: Genomics, Dynamics, and Applications. Annu Rev Virol. 2020;7:37–61. doi: 10.1146/annurev-virology-122019-070009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Fremin BJ, Bhatt AS, Kyrpides NC. Global Phage Small Open Reading Frame (GP-SmORF) Consortium. Thousands of small, novel genes predicted in global phage genomes. Cell Rep. 2022;39:110984. doi: 10.1016/j.celrep.2022.110984 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Roux S, Emerson JB. Diversity in the soil virosphere: to infinity and beyond? Trends Microbiol. 2022;30:1025–1035. doi: 10.1016/j.tim.2022.05.003 [DOI] [PubMed] [Google Scholar]
  • 13.Strathdee SA, Hatfull GF, Mutalik VK, Schooley RT. Phage therapy: From biological mechanisms to future directions. Cell. 2023;186:17–31. doi: 10.1016/j.cell.2022.11.017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mutalik VK, Arkin AP. A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens. iScience. 2022;25:104121. doi: 10.1016/j.isci.2022.104121 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Miller ES, Kutter E, Mosig G, Arisaka F, Kunisawa T, Rüger W. Bacteriophage T4 genome. Microbiol Mol Biol Rev. 2003;67:86–156. table of contents. doi: 10.1128/MMBR.67.1.86-156.2003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Dutilh BE, Reyes A, Hall RJ, Whiteson KL. Editorial: Virus Discovery by Metagenomics: The (Im)possibilities. Front Microbiol. 2017;8:1710. doi: 10.3389/fmicb.2017.01710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Casjens SR, Hendrix RW. Bacteriophage lambda: Early pioneer and still relevant. Virology. 2015;479–480:310–330. doi: 10.1016/j.virol.2015.02.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Molineux I. T7 Bacteriophages. Encyclopedia of Molecular Biology. 2002. doi: 10.1002/047120918x.emb1510 [DOI] [Google Scholar]
  • 19.Pires DP, Cleto S, Sillankorva S, Azeredo J, Lu TK. Genetically Engineered Phages: a Review of Advances over the Last Decade. Microbiol Mol Biol Rev. 2016;80:523–543. doi: 10.1128/MMBR.00069-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Adler BA, Chamakura K, Carion H, Krog J, Deutschbauer AM, Young R, et al. Multicopy suppressor screens reveal convergent evolution of single-gene lysis proteins. Nat Chem Biol. 2023. doi: 10.1038/s41589-023-01269-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Silas S, Carion H, Makarova KS, Laderman E, Godinez DS, Johnson M, et al. Parallelized screening of virus accessory genes reveals diverse defense and counter-defense mechanisms. 2023. doi: 10.1101/2023.04.06.535777 [DOI] [Google Scholar]
  • 22.Marinelli LJ, Piuri M, Swigonova Z, Balachandran A, Oldfield LM, van Kessel JC, et al. BRED: a simple and powerful tool for constructing mutant and recombinant bacteriophage genomes. PLoS ONE. 2008;3:e3957. doi: 10.1371/journal.pone.0003957 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Dedrick RM, Marinelli LJ, Newton GL, Pogliano K, Pogliano J, Hatfull GF. Functional requirements for bacteriophage growth: gene essentiality and expression in mycobacteriophage Giles. Mol Microbiol. 2013;88:577–589. doi: 10.1111/mmi.12210 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Pires DP, Monteiro R, Mil-Homens D, Fialho A, Lu TK, Azeredo J, et al. aeruginosa synthetic phages with reduced genomes. Sci Rep. 2021;11:2164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Mahler M, Costa AR, van Beljouw SPB, Fineran PC, Brouns SJJ. Approaches for bacteriophage genome engineering. Trends Biotechnol. 2022. doi: 10.1016/j.tibtech.2022.08.008 [DOI] [PubMed] [Google Scholar]
  • 26.Mitsunaka S, Yamazaki K, Pramono AK, Ikeuchi M, Kitao T, Ohara N, et al. Synthetic engineering and biological containment of bacteriophages. Proc Natl Acad Sci U S A. 2022;119:e2206739119. doi: 10.1073/pnas.2206739119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Meile S, Du J, Dunne M, Kilcher S, Loessner MJ. Engineering therapeutic phages for enhanced antibacterial efficacy. Curr Opin Virol. 2022;52:182–191. doi: 10.1016/j.coviro.2021.12.003 [DOI] [PubMed] [Google Scholar]
  • 28.Yuan S, Shi J, Jiang J, Ma Y. Genome-scale top-down strategy to generate viable genome-reduced phages. Nucleic Acids Res. 2022;50:13183–13197. doi: 10.1093/nar/gkac1168 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Adler BA, Hessler T, Cress BF, Lahiri A, Mutalik VK, Barrangou R, et al. Broad-spectrum CRISPR-Cas13a enables efficient phage genome editing. Nat Microbiol. 2022;7:1967–1979. doi: 10.1038/s41564-022-01258-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wetzel KS, Guerrero-Bustamante CA, Dedrick RM, Ko C-C, Freeman KG, Aull HG, et al. CRISPY-BRED and CRISPY-BRIP: efficient bacteriophage engineering. Sci Rep. 2021;11:6796. doi: 10.1038/s41598-021-86112-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Guan J, Oromí-Bosch A, Mendoza SD, Karambelkar S, Berry JD, Bondy-Denomy J. Bacteriophage genome engineering with CRISPR-Cas13a. Nat Microbiol. 2022;7:1956–1966. doi: 10.1038/s41564-022-01243-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Nethery MA, Hidalgo-Cantabrana C, Roberts A, Barrangou R. CRISPR-based engineering of phages for in situ bacterial base editing. Proc Natl Acad Sci U S A. 2022;119:e2206744119. doi: 10.1073/pnas.2206744119 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Oechslin F, Zhu X, Dion MB, Shi R, Moineau S. Phage endolysins are adapted to specific hosts and are evolutionarily dynamic. PLoS Biol. 2022;20:e3001740. doi: 10.1371/journal.pbio.3001740 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bock C, Datlinger P, Chardon F, Coelho MA, Dong MB, Lawson KA, et al. High-content CRISPR screening. Nat Rev Methods Primers. 2022;2:1–23. doi: 10.1038/s43586-022-00098-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Przybyla L, Gilbert LA. A new era in functional genomics screens. Nat Rev Genet. 2022;23:89–103. doi: 10.1038/s41576-021-00409-w [DOI] [PubMed] [Google Scholar]
  • 36.Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013;152:1173–1183. doi: 10.1016/j.cell.2013.02.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 2013;41:7429–7437. doi: 10.1093/nar/gkt520 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Zhang X, Wang J, Cheng Q, Zheng X, Zhao G, Wang J. Multiplex gene regulation by CRISPR-ddCpf1. Cell Discov. 2017;3:17018. doi: 10.1038/celldisc.2017.18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kim SK, Kim H, Ahn W-C, Park K-H, Woo E-J, Lee D-H, et al. Efficient transcriptional gene repression by type V-A CRISPR-Cpf1 from Eubacterium eligens. ACS Synth Biol. 2017;6:1273–1282. doi: 10.1021/acssynbio.6b00368 [DOI] [PubMed] [Google Scholar]
  • 40.Specht DA, Xu Y, Lambert G. Massively parallel CRISPRi assays reveal concealed thermodynamic determinants of dCas12a binding. Proc Natl Acad Sci U S A. 2020;117:11274–11282. doi: 10.1073/pnas.1918685117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Hein MY, Weissman JS. Functional single-cell genomics of human cytomegalovirus infection. Nat Biotechnol. 2022;40:391–401. doi: 10.1038/s41587-021-01059-3 [DOI] [PubMed] [Google Scholar]
  • 42.Fleck N, Grundner C. A Cas12a-based CRISPR interference system for multigene regulation in mycobacteria. J Biol Chem. 2021;297:100990. doi: 10.1016/j.jbc.2021.100990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Li L, Wei K, Zheng G, Liu X, Chen S, Jiang W, et al. CRISPR-Cpf1-Assisted Multiplex Genome Editing and Transcriptional Repression in Streptomyces. Appl Environ Microbiol. 2018:84. doi: 10.1128/AEM.00827-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Choi SY, Woo HM. CRISPRi-dCas12a: A dCas12a-Mediated CRISPR Interference for Repression of Multiple Genes and Metabolic Engineering in Cyanobacteria. ACS Synth Biol. 2020;9:2351–2361. doi: 10.1021/acssynbio.0c00091 [DOI] [PubMed] [Google Scholar]
  • 45.Liu Y, Dai L, Dong J, Chen C, Zhu J, Rao VB, et al. Covalent Modifications of the Bacteriophage Genome Confer a Degree of Resistance to Bacterial CRISPR Systems. J Virol. 2020:94. doi: 10.1128/JVI.01630-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Huang CJ, Adler BA, Doudna JA. A naturally DNase-free CRISPR-Cas12c enzyme silences gene expression. Mol Cell. 2022;82:2148–2160.e4. doi: 10.1016/j.molcel.2022.04.020 [DOI] [PubMed] [Google Scholar]
  • 47.Wright BW, Molloy MP, Jaschke PR. Overlapping genes in natural and engineered genomes. Nat Rev Genet. 2022;23:154–168. doi: 10.1038/s41576-021-00417-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Shcherbakov DV, Garber MB. [Overlapping genes in bacterial and bacteriophage genomes]. Mol Biol. 2000;34:572–583. [PubMed] [Google Scholar]
  • 49.Parent KN, Schrad JR, Cingolani G. Breaking Symmetry in Viral Icosahedral Capsids as Seen through the Lenses of X-ray Crystallography and Cryo-Electron Microscopy. Viruses. 2018:10. doi: 10.3390/v10020067 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Wikoff WR, Johnson JE. Virus assembly: Imaging a molecular machine. Curr Biol. 1999;9:R296–R300. doi: 10.1016/s0960-9822(99)80183-3 [DOI] [PubMed] [Google Scholar]
  • 51.Leiman PG, Kanamaru S, Mesyanzhinov VV, Arisaka F, Rossmann MG. Structure and morphogenesis of bacteriophage T4. Cell Mol Life Sci. 2003;60:2356–2370. doi: 10.1007/s00018-003-3072-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Lobocka MB, Rose DJ, Plunkett G 3rd, Rusin M, Samojedny A, Lehnherr H, et al. Genome of bacteriophage P1. J Bacteriol. 2004;186:7032–7068. doi: 10.1128/JB.186.21.7032-7068.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Knott GJ, Cress BF, Liu JJ, Thornton BW, Lew RJ, Al-Shayeb B, et al. Structural basis for AcrVA4 inhibition of specific CRISPR-Cas12a. Elife. 2019:8. doi: 10.7554/eLife.49110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Piya DK. Interactions between host and phage encoded factors shape phage infection. Doctoral dissertation, Texas A & M University. 2018. Available from: https://oaktrust.library.tamu.edu/handle/1969.1/174423
  • 55.Hendrix RW. Lambda II. Cold Spring Harbor Laboratory; 1983. [Google Scholar]
  • 56.Toothman P, Herskowitz I. Rex-dependent exclusion of lambdoid phages. I. Prophage requirements for exclusion. Virology. 1980;102:133–146. doi: 10.1016/0042-6822(80)90076-8 [DOI] [PubMed] [Google Scholar]
  • 57.Gottesman ME, Yarmolinsky MB. The Integration and Excision of the Bacteriophage Lambda Genome. Cold Spring Harb Symp Quant Biol. 1968:735–747. doi: 10.1101/sqb.1968.033.01.084 [DOI] [PubMed] [Google Scholar]
  • 58.Caldwell BJ, Bell CE. Structure and mechanism of the Red recombination system of bacteriophage lambda. Prog Biophys Mol Biol. 2019;147:33–46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Haeusser DP, Hoashi M, Weaver A, Brown N, Pan J, Sawitzke JA, et al. The Kil peptide of bacteriophage lambda blocks Escherichia coli cytokinesis via ZipA-dependent inhibition of FtsZ assembly. PLoS Genet. 2014;10:e1004217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Zabeau M, Friedman S, Van Montagu M, Schell J. The ral gene of phage lambda. I. Identification of a non-essential gene that modulates restriction and modification in E. coli. Mol Gen Genet. 1980;179:63–73. doi: 10.1007/BF00268447 [DOI] [PubMed] [Google Scholar]
  • 61.Debrouwere L, Zabeau M, Van Montagu M, Schell J. The ral gene of phage lambda. II. Isolation and characterization of ral deficient mutants. Mol Gen Genet. 1980;179:75–80. doi: 10.1007/BF00268448 [DOI] [PubMed] [Google Scholar]
  • 62.Hendrix RW, Duda RL. Bacteriophage lambda PaPa: not the mother of all lambda phages. Science. 1992;258:1145–1148. doi: 10.1126/science.1439823 [DOI] [PubMed] [Google Scholar]
  • 63.Cheng SW, Court DL, Friedman DI. Transcription termination signals in the nin region of bacteriophage lambda: identification of Rho-dependent termination regions. Genetics. 1995;140:875–887. doi: 10.1093/genetics/140.3.875 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Kroger M, Hobom G. A chain of interlinked genes in the nin R region of bacteriophage lambda. Gene. 1982;20:25–38. doi: 10.1016/0378-1119(82)90084-1 [DOI] [PubMed] [Google Scholar]
  • 65.Court D, Sato K. Studies of novel transducing variants of lambda: dispensability of genes N and Q. Virology. 1969;39:348–352. doi: 10.1016/0042-6822(69)90060-9 [DOI] [PubMed] [Google Scholar]
  • 66.Rousset F, Cui L, Siouve E, Becavin C, Depardieu F, Bikard D. Genome-wide CRISPR-dCas9 screens in E. coli identify essential genes and phage host factors. PLoS Genet. 2018;14:e1007749. doi: 10.1371/journal.pgen.1007749 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Liu X, Gallay C, Kjos M, Domenech A, Slager J, Kessel SP, et al. High-throughput CRISPRi phenotyping identifies new essential genes in Streptococcus pneumoniae. Mol Syst Biol. 2017;13:931. doi: 10.15252/msb.20167449 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Peters JM, Colavin A, Shi H, Czarny TL, Larson MH, Wong S, et al. A Comprehensive, CRISPR-based Functional Analysis of Essential Genes in Bacteria. Cell. 2016;165:1493–1506. doi: 10.1016/j.cell.2016.05.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Wang T, Guan C, Guo J, Liu B, Wu Y, Xie Z, et al. Pooled CRISPR interference screening enables genome-scale functional genomics study in bacteria with superior performance. Nat Commun. 2018;9:2475. doi: 10.1038/s41467-018-04899-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Rishi HS, Toro E, Liu H, Wang X, Qi LS, Arkin AP. Systematic genome-wide querying of coding and non-coding functional elements in E. coli using CRISPRi. bioRxiv. 2020. p. 2020.03.04.975888. doi: 10.1101/2020.03.04.975888 [DOI] [Google Scholar]
  • 71.Friedman DI, Court DL. Transcription antitermination: the lambda paradigm updated. Mol Microbiol. 1995;18:191–200. doi: 10.1111/j.1365-2958.1995.mmi_18020191.x [DOI] [PubMed] [Google Scholar]
  • 72.Gründling A, Manson MD, Young R. Holins kill without warning. Proc Natl Acad Sci U S A. 2001;98:9348–9352. doi: 10.1073/pnas.151247598 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Gonzales MF, Piya DK, Koehler B, Zhang K, Yu Z, Zeng L, et al. New Insights into the Structure and Assembly of Bacteriophage P1. Viruses. 2022:14. doi: 10.3390/v14040678 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Windle BE, Laufer CS, Hays JB. Sequence and deletion analysis of the recombination enhancement gene (ref) of bacteriophage P1: evidence for promoter-operator and attenuator-antiterminator control. J Bacteriol. 1988;170:4881–4889. doi: 10.1128/jb.170.10.4881-4889.1988 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Wetmore KM, Price MN, Waters RJ, Lamson JS, He J, Hoover CA, et al. Rapid quantification of mutant fitness in diverse bacteria by sequencing randomly bar-coded transposons. MBio. 2015;6:e00306–e00315. doi: 10.1128/mBio.00306-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76.Mutalik VK, Adler BA, Rishi HS, Piya D, Zhong C, Koskella B, et al. High-throughput mapping of the phage resistance landscape in E. coli. PLoS Biol. 2020;18:e3000877. doi: 10.1371/journal.pbio.3000877 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Jiang W, Oikonomou P, Tavazoie S. Comprehensive Genome-wide Perturbations via CRISPR Adaptation Reveal Complex Genetics of Antibiotic Sensitivity. Cell. 2020;180:1002–1017.e31. doi: 10.1016/j.cell.2020.02.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Liu X, Jiang H, Gu Z, Roberts JW. High-resolution view of bacteriophage lambda gene expression by ribosome profiling. Proc Natl Acad Sci U S A. 2013;110:11928–11933. doi: 10.1073/pnas.1309739110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Hall PM, Inman JT, Fulbright RM, Le TT, Brewer JJ, Lambert G, et al. Polarity of the CRISPR roadblock to transcription. Nat Struct Mol Biol. 2022;29:1217–1227. doi: 10.1038/s41594-022-00864-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Adler BA, Al-Shimary MJ, Patel JR, Armbruster E, Colognori D, Charles EJ, et al. Genome-wide Characterization of Diverse Bacteriophages Enabled by RNA-Binding CRISPRi. bioRxiv. 2023:p. 2023.09.18.558157. doi: 10.1101/2023.09.18.558157 [DOI] [Google Scholar]
  • 81.Carlson HK, Piya D, Moore ML, Magar RT, Elisabeth NH, Deutschbauer AM, et al. Geochemical constraints on bacteriophage infectivity in terrestrial environments. bioRxiv. 2023. p. 2023.04.10.536276. doi: 10.1038/s43705-023-00297-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Wang JY, Doudna JA. CRISPR technology: A decade of genome editing is only the beginning. Science. 2023;379:eadd8643. doi: 10.1126/science.add8643 [DOI] [PubMed] [Google Scholar]
  • 83.Adams MH. Bacteriophages. New York, NY: Interscience Publishers; 1959. [Google Scholar]
  • 84.Pryor JM, Potapov V, Kucera RB, Bilotti K, Cantor EJ, Lohman GJS. Enabling one-pot Golden Gate assemblies of unprecedented complexity using data-optimized assembly design. PLoS ONE. 2020;15:e0238592. doi: 10.1371/journal.pone.0238592 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Guzman LM, Belin D, Carson MJ, Beckwith J. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. J Bacteriol. 1995;177:4121–4130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Bari SMN, Walker FC, Cater K, Aslan B, Hatoum-Aslan A. Strategies for Editing Virulent Staphylococcal Phages Using CRISPR-Cas10. ACS Synth Biol. 2017;6:2316–2325. doi: 10.1021/acssynbio.7b00240 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Gibson DG, Young L, Chuang RY, Venter JC, Hutchison CA 3rd, Smith HO. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods. 2009;6:343–345. doi: 10.1038/nmeth.1318 [DOI] [PubMed] [Google Scholar]
  • 88.Chung CT, Niemela SL, Miller RH. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Proc Natl Acad Sci U S A. 1989;86:2172–2175. doi: 10.1073/pnas.86.7.2172 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 89.Hupfeld M, Trasanidou D, Ramazzini L, Klumpp J, Loessner MJ, Kilcher S. A functional type II-A CRISPR-Cas system from Listeria enables efficient genome editing of large non-integrating bacteriophage. Nucleic Acids Res. 2018;46:6920–6933. doi: 10.1093/nar/gky544 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Price MN, Ray J, Iavarone AT, Carlson HK, Ryan EM, Malmstrom RR, et al. Oxidative Pathways of Deoxyribose and Deoxyribonate Catabolism. mSystems. 2019:4. doi: 10.1128/mSystems.00297-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Weisberg RA, Sternberg N, Gallay E. The nu1 gene of coliphage lambda. Virology. 1979;95:99–106. doi: 10.1016/0042-6822(79)90404-5 [DOI] [PubMed] [Google Scholar]
  • 92.Harrison DP, Brown DT, Bode VC. The lambda head-tail joining reaction: purification, properties and structure of biologically active heads and tails. J Mol Biol. 1973;79:437–449. doi: 10.1016/0022-2836(73)90397-5 [DOI] [PubMed] [Google Scholar]
  • 93.Kaiser D, Syvanen M, Masuda T. Processing and assembly of the head of bacteriophage lambda. J Supramol Struct. 1974;2:318–328. doi: 10.1002/jss.400020221 [DOI] [PubMed] [Google Scholar]
  • 94.Boklage CE, Wong EC, Bode VC. Functional abnormality of lambda phage particles from complemented FII-mutant lysates. Virology. 1974;61:22–28. doi: 10.1016/0042-6822(74)90238-4 [DOI] [PubMed] [Google Scholar]
  • 95.Medina E, Wieczorek D, Medina EM, Yang Q, Feiss M, Catalano CE. Assembly and maturation of the bacteriophage lambda procapsid: gpC is the viral protease. J Mol Biol. 2010;401:813–830. doi: 10.1016/j.jmb.2010.06.060 [DOI] [PubMed] [Google Scholar]
  • 96.Ray P, Murialdo H. The role of gene Nu3 in bacteriophage lambda head morphogenesis. Virology. 1975;64:247–263. doi: 10.1016/0042-6822(75)90096-3 [DOI] [PubMed] [Google Scholar]
  • 97.Hohn B, Hohn T. Activity of empty, headlike particles for packaging of DNA of bacteriophage lambda in vitro. Proc Natl Acad Sci U S A. 1974;71:2372–2376. doi: 10.1073/pnas.71.6.2372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Catalano CE, Tomka MA. Role of gpFI protein in DNA packaging by bacteriophage lambda. Biochemistry. 1995;34:10036–10042. doi: 10.1021/bi00031a027 [DOI] [PubMed] [Google Scholar]
  • 99.Kemp CL, Howatson AF, Siminovitch L. Electron microscopy studies of mutants of lambada bacteriophage. I. General description and quantitation of viral products. Virology. 1968;36:490–502. doi: 10.1016/0042-6822(68)90174-8 [DOI] [PubMed] [Google Scholar]
  • 100.Szybalski EH, Szybalski W. A comprehensive molecular map of bacteriophage lambda. Gene. 1979;7:217–270. doi: 10.1016/0378-1119(79)90047-7 [DOI] [PubMed] [Google Scholar]
  • 101.Enquist LW, Skalka A. Replication of bacteriophage lambda DNA dependent on the function of host and viral genes. I. Interaction of red, gam and rec. J Mol Biol. 1973;75:185–212. doi: 10.1016/0022-2836(73)90016-8 [DOI] [PubMed] [Google Scholar]
  • 102.Greer H. The kil gene of bacteriophage lambda. Virology. 1975;66:589–604. doi: 10.1016/0042-6822(75)90231-7 [DOI] [PubMed] [Google Scholar]
  • 103.Kaiser AD. Mutations in a temperate bacteriophage affecting its ability to lysogenize Escherichia coli. Virology. 1957;3:42–61. doi: 10.1016/0042-6822(57)90022-3 [DOI] [PubMed] [Google Scholar]
  • 104.Truitt CL, Chu H, Walker JR. Bacteriophage lambda mutants (lambdatp) that overproduce repressor. J Virol. 1978;28:877–884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Campbell A. Comparative molecular biology of lambdoid phages. Annu Rev Microbiol. 1994;48:193–222. doi: 10.1146/annurev.mi.48.100194.001205 [DOI] [PubMed] [Google Scholar]
  • 106.Radding CM. Nuclease activity in defective lysogens of phage lambda. Biochem Biophys Res Commun. 1964;15:8–12. doi: 10.1016/0006-291x(64)90093-2 [DOI] [PubMed] [Google Scholar]
  • 107.Galland P, Cortini R, Calef E. Control of gene expression in bacteriophage lambda: suppression of N mutants by mutations of the antirepressor. Mol Gen Genet. 1975;142:155–170. doi: 10.1007/BF00266096 [DOI] [PubMed] [Google Scholar]
  • 108.Thomas R, Lambert L. On the occurrence of bacterial mutations permitting lysogenization by clear variants of temperate bacteriophages. J Mol Biol. 1962;5:373–374. doi: 10.1016/s0022-2836(62)80079-5 [DOI] [PubMed] [Google Scholar]
  • 109.Lieb M. Mapping missense and nonsense mutation in gene cI of bacteriophage lambda: marker effects. Mol Gen Genet. 1976;146:285–290. doi: 10.1007/BF00701252 [DOI] [PubMed] [Google Scholar]
  • 110.Eisen H, Brachet P, Pereira da Silva L, Jacob F. Regulation of repressor expression in lambda. Proc Natl Acad Sci U S A. 1970;66:855–862. doi: 10.1073/pnas.66.3.855 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Kleckner N. Amber mutants in the O gene of bacteriophage lambda are not efficiently complemented in the absence of phage N function. Virology. 1977;79:174–182. doi: 10.1016/0042-6822(77)90343-9 [DOI] [PubMed] [Google Scholar]
  • 112.Mukai T, Ohkubo H, Shimada K, Takagi Y. Isolation and characterization of a plaque-forming lambda bacteriophage carrying a ColE1 plasmid. J Bacteriol. 1978;135:171–177. doi: 10.1128/jb.135.1.171-177.1978 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Tarkowski TA, Mooney D, Thomason LC, Stahl FW. Gene products encoded in the ninR region of phage lambda participate in Red-mediated recombination. Genes Cells. 2002;7:351–363. doi: 10.1046/j.1365-2443.2002.00531.x [DOI] [PubMed] [Google Scholar]
  • 114.Chang CY, Nam K, Young R. S gene expression and the timing of lysis by bacteriophage lambda. J Bacteriol. 1995;177:3283–3294. doi: 10.1128/jb.177.11.3283-3294.1995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 115.Young R. Phage lysis: three steps, three choices, one outcome. J Microbiol. 2014;52:243–258. doi: 10.1007/s12275-014-4087-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Zhang N, Young R. Complementation and characterization of the nested Rz and Rz1 reading frames in the genome of bacteriophage lambda. Mol Gen Genet. 1999;262:659–667. doi: 10.1007/s004380051128 [DOI] [PubMed] [Google Scholar]
  • 117.Sternberg N, Sauer B, Hoess R, Abremski K. Bacteriophage P1 cre gene and its regulatory region. Evidence for multiple promoters and for regulation by DNA methylation. J Mol Biol. 1986;187:197–212. doi: 10.1016/0022-2836(86)90228-7 [DOI] [PubMed] [Google Scholar]
  • 118.Lu SD, Lu D, Gottesman M. Stimulation of IS1 excision by bacteriophage P1 ref function. J Bacteriol. 1989;171:3427–3432. doi: 10.1128/jb.171.6.3427-3432.1989 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 119.Lehnherr H, Jensen CD, Stenholm AR, Dueholm A. Dual regulatory control of a particle maturation function of bacteriophage P1. J Bacteriol. 2001;183:4105–4109. doi: 10.1128/JB.183.14.4105-4109.2001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 120.Iida S, Meyer J, Bachi B, Stalhammar-Carlemalm M, Schrickel S, Bickle TA, et al. DNA restriction—modification genes of phage P1 and plasmid p15B. Structure and in vitro transcription. J Mol Biol. 1983;165:1–18. doi: 10.1016/s0022-2836(83)80239-3 [DOI] [PubMed] [Google Scholar]
  • 121.Schaefer TS, Hays JB. The bof gene of bacteriophage P1: DNA sequence and evidence for roles in regulation of phage c1 and ref genes. J Bacteriol. 1990;172:3269–3277. doi: 10.1128/jb.172.6.3269-3277.1990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Piya D, Vara L, Russell WK, Young R, Gill JJ. The multicomponent antirestriction system of phage P1 is linked to capsid morphogenesis. Mol Microbiol. 2017;105:399–412. doi: 10.1111/mmi.13705 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Schmidt C, Velleman M, Arber W. Three functions of bacteriophage P1 involved in cell lysis. J Bacteriol. 1996;178:1099–1104. doi: 10.1128/jb.178.4.1099-1104.1996 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 124.Iida S, Arber W. Plaque forming specialized transducing phage P1: isolation of P1CmSmSu, a precursor of P1Cm. Mol Gen Genet. 1977;153:259–269. doi: 10.1007/BF00431591 [DOI] [PubMed] [Google Scholar]
  • 125.Iida S, Meyer J, Kennedy KE, Arber W. A site-specific, conservative recombination system carried by bacteriophage P1. Mapping the recombinase gene cin and the cross-over sites cix for the inversion of the C segment. EMBO J. 1982;1:1445–1453. doi: 10.1002/j.1460-2075.1982.tb01336.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 126.Iida S. Bacteriophage P1 carries two related sets of genes determining its host range in the invertible C segment of its genome. Virology. 1984;134:421–434. doi: 10.1016/0042-6822(84)90309-x [DOI] [PubMed] [Google Scholar]
  • 127.Guidolin A, Zingg JM, Arber W. Organization of the bacteriophage P1 tail-fibre operon. Gene. 1989;76:239–243. doi: 10.1016/0378-1119(89)90164-9 [DOI] [PubMed] [Google Scholar]
  • 128.Walker JT, Walker DH Jr. Coliphage P1 morphogenesis: analysis of mutants by electron microscopy. J Virol. 1983;45:1118–1139. doi: 10.1128/JVI.45.3.1118-1139.1983 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129.Devlin BH, Baumstark BR, Scott JR. Superimmunity: characterization of a new gene in the immunity region of P1. Virology. 1982;120:360–375. doi: 10.1016/0042-6822(82)90037-x [DOI] [PubMed] [Google Scholar]
  • 130.Heinrich J, Citron M, Gunther A, Schuster H. Second-site suppressors of the bacteriophage P1 virs mutant reveal the interdependence of the c4, icd, and ant genes in the P1 immI operon. J Bacteriol. 1994;176:4931–4936. doi: 10.1128/jb.176.16.4931-4936.1994 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Hansen EB. Structure and regulation of the lytic replicon of phage P1. J Mol Biol. 1989;207:135–149. doi: 10.1016/0022-2836(89)90445-2 [DOI] [PubMed] [Google Scholar]
  • 132.Coulby JN, Sternberg NL. Characterization of the phage P1 dam gene. Gene. 1988;74:191. doi: 10.1016/0378-1119(88)90284-3 [DOI] [PubMed] [Google Scholar]
  • 133.D’Ari R, Jaffe-Brachet A, Touati-Schwartz D, Yarmolinsky MB. A dnaB analog specified by bacteriophage P1. J Mol Biol. 1975;94:341–366. doi: 10.1016/0022-2836(75)90207-7 [DOI] [PubMed] [Google Scholar]
  • 134.Lehnherr H, Guidolin A, Arber W. Bacteriophage P1 gene 10 encodes a trans-activating factor required for late gene expression. J Bacteriol. 1991;173:6438–6445. doi: 10.1128/jb.173.20.6438-6445.1991 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 135.Skorupski K, Pierce JC, Sauer B, Sternberg N. Bacteriophage P1 genes involved in the recognition and cleavage of the phage packaging site (pac). J Mol Biol. 1992;223:977–989. doi: 10.1016/0022-2836(92)90256-j [DOI] [PubMed] [Google Scholar]
  • 136.Baumstark BR, Stovall SR, Bralley P. The ImmC region of phage P1 codes for a gene whose product promotes lytic growth. Virology. 1990;179:217–227. doi: 10.1016/0042-6822(90)90291-x [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Paula Jauregui, PhD

2 Jun 2023

Dear Dr. Mutalik,

Thank you for submitting your manuscript entitled "Genome-wide CRISPRi knockdown to map gene essentiality landscape in coliphages λ and P1" for consideration as a Research Article by PLOS Biology.

Your manuscript has now been evaluated by the PLOS Biology editorial staff, as well as by an academic editor with relevant expertise, and I am writing to let you know that we would like to send your submission out for external peer review as a Methods and Resources article.

Methods and Resources Articles describe technical innovations, including novel approaches to a previously inaccessible biological innovation, or substantial improvements over previously established methods. The reported method should be thoroughly validated, and while presenting new biological insights is encouraged, this is not a requirement for consideration. Resources consist of data sets or other significant scientific resources that are of general interest and provide exceptionally value for the community that could spur future research.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. After your manuscript has passed the checks it will be sent out for review. To provide the metadata for your submission, please Login to Editorial Manager (https://www.editorialmanager.com/pbiology) within two working days, i.e. by Jun 04 2023 11:59PM.

If your manuscript has been previously peer-reviewed at another journal, PLOS Biology is willing to work with those reviews in order to avoid re-starting the process. Submission of the previous reviews is entirely optional and our ability to use them effectively will depend on the willingness of the previous journal to confirm the content of the reports and share the reviewer identities. Please note that we reserve the right to invite additional reviewers if we consider that additional/independent reviewers are needed, although we aim to avoid this as far as possible. In our experience, working with previous reviews does save time.

If you would like us to consider previous reviewer reports, please edit your cover letter to let us know and include the name of the journal where the work was previously considered and the manuscript ID it was given. In addition, please upload a response to the reviews as a 'Prior Peer Review' file type, which should include the reports in full and a point-by-point reply detailing how you have or plan to address the reviewers' concerns.

During the process of completing your manuscript submission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit http://journals.plos.org/plosbiology/s/preprints for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF.

Feel free to email us at plosbiology@plos.org if you have any queries relating to your submission.

Kind regards,

Paula

---

Paula Jauregui, PhD,

Senior Editor

PLOS Biology

pjaureguionieva@plos.org

Decision Letter 1

Paula Jauregui, PhD

7 Jul 2023

Dear Dr. Mutalik,

Thank you for your patience while your manuscript "Genome-wide CRISPRi knockdown to map gene essentiality landscape in coliphages λ and P1" was peer-reviewed at PLOS Biology. It has now been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by several independent reviewers.

In light of the reviews, which you will find at the end of this email, we would like to invite you to revise the work to thoroughly address the reviewers' reports.

As you will see below, reviewers #1 and #2 agree that the method will be very useful for the community, but all the reviewers find issues that will need to be solved before further consideration. Reviewer #3 asks for mechanistic insights, but these are not needed for Methods and Resources manuscripts. We think that you should address all the issues raised by reviewers #1 and #2 and especially the notion of whether this is broadly applicable to other phages.

Given the extent of revision needed, we cannot make a decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is likely to be sent for further evaluation by all or a subset of the reviewers.

We expect to receive your revised manuscript within 3 months. Please email us (plosbiology@plos.org) if you have any questions or concerns, or would like to request an extension.

At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not intend to submit a revision so that we may withdraw it.

**IMPORTANT - SUBMITTING YOUR REVISION**

Your revisions should address the specific points made by each reviewer. Please submit the following files along with your revised manuscript:

1. A 'Response to Reviewers' file - this should detail your responses to the editorial requests, present a point-by-point response to all of the reviewers' comments, and indicate the changes made to the manuscript.

*NOTE: In your point-by-point response to the reviewers, please provide the full context of each review. Do not selectively quote paragraphs or sentences to reply to. The entire set of reviewer comments should be present in full and each specific point should be responded to individually, point by point.

You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response.

2. In addition to a clean copy of the manuscript, please also upload a 'track-changes' version of your manuscript that specifies the edits made. This should be uploaded as a "Revised Article with Changes Highlighted" file type.

*Re-submission Checklist*

When you are ready to resubmit your revised manuscript, please refer to this re-submission checklist: https://plos.io/Biology_Checklist

To submit a revised version of your manuscript, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' where you will find your submission record.

Please make sure to read the following important policies and guidelines while preparing your revision:

*Published Peer Review*

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/

*PLOS Data Policy*

Please note that as a condition of publication PLOS' data policy (http://journals.plos.org/plosbiology/s/data-availability) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5

*Blot and Gel Data Policy*

We require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements

*Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Paula

---

Paula Jauregui, PhD,

Senior Editor

PLOS Biology

pjaureguionieva@plos.org

------------------------------------

REVIEWS:

Reviewer #1: Phage therapy.

Reviewer #2: Phage biology.

Reviewer #3: Phages and CRISPR.

Reviewer #1: This paper by Piya et al. primarily describes the deployment of CRISPRi via dCas12a to globally assess gene essentiality within two model bacteriophage. Using their identification of non-essential regions of the phage genomes in a practical example they then place genetic barcodes into phage lambda and P1 genomes and show how these can be used to enumerate and track phage populations within a mixed culture.

Overall, the paper is very clearly written and the logic and reasoning behind the experiments is well explained. The work is important and would be expected to be broadly applicable across at least the dsDNA phages, and likely ssDNA phages as well (although no example is given) that infect E. coli and closely related species. The plasmids as they are currently configured may not function in more distant host groups, but the principle outlined in this work should still hold if porting over to different bacterial families. The materials in the work are very well described and using the plasmids with different CRISPRi oligos would be straightforward. If the authors have not already, I encourage them to deposit the plasmids with Addgene so they are easily accessible.

I have a few comments:

Figures: I'm not sure if this is due to the journal's reformatting of PDFs, but most of the figures show as fuzzy and some text is illegible (e.g. Fig 1)

Both phage lambda and P1 are temperate phage and I was wondering as I read the paper how you were dealing with that possibility. I see it explained in the Materials and Methods, but it would be good to mention in the main text that variants being used in the work are lysogen-deficient.

The non-targeting crRNA was not fully described in the text. For example, what does it target? Is it similar GC-content to other oligos used?

The pros and cons of using dCas12a versus dCas9 are not discussed sufficiently. Why was dCas12a chosen? Would you expect similar results with dCas9? Why or why not?

Amber mutants are treated as "ground truth" in this work, but have the authors thought about whether some amber mutants may also be polar mutations? Translation is thought to protect transcripts from degradation and if translation is stopped over a large section of mRNA this may destabilize the transcript causing a polar effect. One older article seems to show this may be possible (https://doi.org/10.1016/0022-2836(68)90144-7) although the phage is very different that lambda or P1.

Supplementary is misspelled in several different parts of the manuscript

Figure 4: the color choice for essential (red) and intermediate phenotype (purple) is not discernible in the figures. Need to change colors so they have more contrast. It would also be very helpful to harmonize the colors between Fig 3, 4 and Tables 1 and 2.

Table 2: The EOP average column has a large number of instances of "essential" instead of a quantitative measure, which is confusing.

The "Downstream application" section is not introduced with sufficient detail to really understand what is going on with the experiments. For example, how long are the phage cultured before measuring? This is pertinent because small fitness defects would be expected to have a detectable effect over large numbers of generations. Fig 5C it is impossible to differentiate the symbols.

Reviewer #2: The manuscript by Piya et al. from the Arkin and Mutalik labs reports the application of CRISPRi to bacteriophages using a setup based on catalytically inactive Cas12a. In difference to previous work using similar technology, the authors target (almost) every gene in two phages and thus report on the first true genome-wide CRISPRi screens in bacterial viruses. This is certainly a breakthrough for the field, but in the current form constitutes rather quantitative than qualitative progress compared to previous work. The paper is very well written and structured comprehensibly. The methodology is described very nicely with considerable detail which would facilitate wide application of the authors' technology.

The introduction appropriately introduces the great need for genome-wide screens in bacteriophages to probe the biological functions of the vast amount of phage genes of unknown function. However, it is not optimal that CRISPR-Cas12a and its use for CRISPRi are just dropped onto the non-expert reader without further explanations. I would therefore suggest to (at least very shortly) introduce the key differences between CRISPR-Cas9 (that many readers have likely heard about) and CRISPR-Cas12a to explain why the authors chose the latter and not the former, even though CRISPR-Cas9 is by far most often used for microbial CRISPRi. Furthermore, I feel that previous use of genome-wide CRISPRi to study viral biology needs to be referenced (Hein and Weissman, Nature Biotechnology (2021)) and explained with view to the question why the same approach could not be simply applied to bacteriophages.

The results section begins with a nicely comprehensible and detailed description of how the authors set up CRISPRi using dCas12a. The authors' validation of the system's basic functionality to distinguish between essential and non-essential genes is very convincing. However, in my view the quantification of knockdown phenotypes in figure 1 is not optimal, though I acknowledge that this is a never-ending discussion in the field. The authors write about a 10'5- to 10'6fold reduction in plating efficiency (line 126). However, there is no plaque formation visible for the knockdowns of essential genes, only "lysis from without". I therefore find it misleading to talk about a reduction in plating because no plating (i.e., plaque formation) can be seen.

Subsequently, the authors use their CRISPRi approach to query (near-)genome-wide gene essentiality in phages lambda and P1 gene by gene. These phages were chosen because generations of researchers have already generated a considerable body of work on gene essentiality for these phages which provides a very convincing benchmark for the authors' technology. The results are indeed largely in line with expectations from previous literature. However, the authors also observe both polar effects and consequences of incomplete knockdowns. These are known downsides of CRISPRi per se and thus do not constitute a specific problem of the authors' approach, even though they later discuss (but do not try) overcoming at least some of the polar effects by using catalytically inactive Cas13a instead of Cas12a.

At the end, the authors inserted barcodes at different loci of their two model phages that their knockdown approach had identified or validated as being not essential. As expected, these barcodes can be used to quantify the abundance of different phage mutants in pools using BarSeq. However, in the current form these experiments seem added onto the manuscript without any real benefit. Different non-essential regions that could be targeted by barcode insertion have already been known before and a small barcode is hardly a difficult payload to insert, so this does not provide a significant advance and has otherwise nothing to do with the methodology that the authors present. In my view this section should either be removed or expanded in a way that connects it better to the rest of the work (e.g., by directly performing phenotypic selection experiments with pooled libraries of barcoded sgRNAs, if the authors like to use BarSeq for an approach similar to CRISPRi-Seq).

The discussion section appropriately places the authors' work into context of the literature and the research problem as defined in the introduction section. Subsequently, the authors discuss different shortcomings of their approach and possible solutions or applications. These parts were interesting but - because they paraphrased a lot of content from the results section - could be easily streamlined and shortened. The authors have included very nice supplementary notes with additional details that are of interest primarily for phage aficionados (greatly appreciated).

In my view this work definitely establishes genome-wide CRISPRi screens for bacteriophages, even though most of the technology has already been around and was used previously for phages (albeit certainly not at the same scale). Furthermore, even (kind-of) CRISPRi-Seq in a virus has already been reported previously for human cytomegalovirus (Hein and Weissmann, Nature Biotechnology 2021 (not cited)). I therefore feel that the authors need to provide additional arguments why their technology is a great advance compared to previous tools. This could be done in different ways. One possibility that comes to my mind would be pooled CRISPRi screens as suggested by the authors themselves in the discussion section to identify different conditionally essential genes in lambda and P1 (and possibly additional phages). Another possibility would be to show if / that the authors' technology can be applied to phages that are (unlike lambda or P1) highly resilient to DNA-targeting tools like CRISPR-Cas. This is true for many phages including, e.g., well-studied lab phages T4 (due to covalent genome modification) and T5 (unknown mechanism) and could greatly limit the applicability of this technology.

Minor points:

1) The manuscript text in line 126 talks about the mcp gene of P1 in Figure 1 but the corresponding lane in the efficiency-of-plating assay is labeled 23. Even though this is explained in the figure legend I would suggest to directly label the EOP assay mcp instead of 23.

2) The authors show that a knockdown of ral has no phenotype because the indicator strain that they use has no active restriction-modification system (lines 172-174). It is for sure not critical but would be quite cool to show that this gene is conditionally essential for growth on a strain with an active restriction-modification system, highlighting the potential of the authors' technology for the investigation of phage-encoded anti-immunity factors.

Reviewer #3: This manuscript describes a method for performing CRISPRi on phage genes. A plasmid system for the expression of a catalytically inactive Cas12 and guide RNA molecules in E. coli was designed. Genes were targeted in two model E. coli phages, lambda and P1. The authors show that targeting of essential genes led to large reductions in phage replication while targeting non-essential genes generally did not affect replication. The difficulties in using this method on phages are highlighted.

This manuscript clearly demonstrates that the catalytically dead version of Cas12 can block phage replication. This is a result of interest, but not particularly surprising given previously published papers in this area. The problems with this approach for evaluating gene essentiality in phage genomes are important and predictable. Given the large number of polycistronic messages in phage genomes, polarity is bound to be a problem. This manuscript has value in confirming that polarity is a major problem for interpreting this type of experiment performed on phages.

While this manuscript contains data of interest, I do not think that it warrants publication in a journal at the level of PLoS Biology. To warrant publication, the authors would need to provide some mechanistic insight into how this CRISPRi system is functioning on the phage genome. While they hypothesize about the effects of polarity, no experiments are performed to address this issue (e.g. RT-qPCR). As presented, I would conclude that CRISPRi is really not a good method to assess essentiality in phages. This manuscript makes the problems evident, but does not provide insight as to how these problems might be overcome.

Decision Letter 2

Paula Jauregui, PhD

20 Oct 2023

Dear Dr. Mutalik,

Thank you for your patience while we considered your revised manuscript "Genome-wide CRISPRi knockdown to map gene essentiality landscape in coliphages λ and P1" for publication as a Methods and Resources at PLOS Biology. This revised version of your manuscript has been evaluated by the PLOS Biology editors and the Academic Editor.

Based on our Academic Editor's assessment of your revision, we are likely to accept this manuscript for publication, provided you satisfactorily address the following data and other policy-related requests.

1. DATA POLICY:

You may be aware of the PLOS Data Policy, which requires that all data be made available without restriction: http://journals.plos.org/plosbiology/s/data-availability. For more information, please also see this editorial: http://dx.doi.org/10.1371/journal.pbio.1001797

Note that we do not require all raw data. Rather, we ask that all individual quantitative observations that underlie the data summarized in the figures and results of your paper be made available in one of the following forms:

A) Supplementary files (e.g., excel). Please ensure that all data files are uploaded as 'Supporting Information' and are invariably referred to (in the manuscript, figure legends, and the Description field when uploading your files) using the following format verbatim: S1 Data, S2 Data, etc. Multiple panels of a single or even several figures can be included as multiple sheets in one excel file that is saved using exactly the following convention: S1_Data.xlsx (using an underscore).

B) Deposition in a publicly available repository. Please also provide the accession code or a reviewer link so that we may view your data before publication.

Regardless of the method selected, please ensure that you provide the individual numerical values that underlie the summary data displayed in the following figure panels as they are essential for readers to assess your analysis and to reproduce it: Figure 5BC.

NOTE: the numerical data provided should include all replicates AND the way in which the plotted mean and errors were derived (it should not present only the mean/average values).

Please also ensure that figure legends in your manuscript include information on where the underlying data can be found, and ensure your supplemental data file/s has a legend.

Please ensure that your Data Statement in the submission system accurately describes where your data can be found.

2. Please provide a blurb which (if accepted) will be included in our weekly and monthly Electronic Table of Contents, sent out to readers of PLOS Biology, and may be used to promote your article in social media. The blurb should be about 30-40 words long and is subject to editorial changes. It should, without exaggeration, entice people to read your manuscript. It should not be redundant with the title and should not contain acronyms or abbreviations.

3. We recommend a change in the title: "Systematic and scalable genome-wide essentiality mapping to identify non-essential genes in phages" or "Systematic and scalable genome-wide essentiality mapping to identify non-essential genes in phages - proof of concept with coliphages λ and P1".

As you address these items, please take this last chance to review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the cover letter that accompanies your revised manuscript.

We expect to receive your revised manuscript within two weeks.

To submit your revision, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' to find your submission record. Your revised submission must include the following:

- a cover letter that should detail your responses to any editorial requests, if applicable, and whether changes have been made to the reference list

- a Response to Reviewers file that provides a detailed response to the reviewers' comments (if applicable, if not applicable please do not delete your existing 'Response to Reviewers' file.)

- a track-changes file indicating any changes that you have made to the manuscript.

NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines:

https://journals.plos.org/plosbiology/s/supporting-information

*Published Peer Review History*

Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/

*Press*

Should you, your institution's press office or the journal office choose to press release your paper, please ensure you have opted out of Early Article Posting on the submission form. We ask that you notify us as soon as possible if you or your institution is planning to press release the article.

*Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please do not hesitate to contact me should you have any questions.

Sincerely,

Paula

---

Paula Jauregui, PhD,

Senior Editor,

pjaureguionieva@plos.org,

PLOS Biology

Decision Letter 3

Paula Jauregui, PhD

2 Nov 2023

Dear Dr Mutalik,

Thank you for the submission of your revised Methods and Resources "Systematic and scalable genome-wide essentiality mapping to identify non-essential genes in phages" for publication in PLOS Biology. On behalf of my colleagues and the Academic Editor, Michael Laub, I am pleased to say that we can in principle accept your manuscript for publication, provided you address any remaining formatting and reporting issues. These will be detailed in an email you should receive within 2-3 business days from our colleagues in the journal operations team; no action is required from you until then. Please note that we will not be able to formally accept your manuscript and schedule it for publication until you have completed any requested changes.

Please take a minute to log into Editorial Manager at http://www.editorialmanager.com/pbiology/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process.

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with biologypress@plos.org. If you have previously opted in to the early version process, we ask that you notify us immediately of any press plans so that we may opt out on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

Thank you again for choosing PLOS Biology for publication and supporting Open Access publishing. We look forward to publishing your study. 

Sincerely, 

Paula

---

Paula Jauregui, PhD,

Senior Editor

PLOS Biology

pjaureguionieva@plos.org

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Lambda phage genome CRISPRi oligo designs.

    Blue represents genes, red represents primers, and black is the full genome. Outside is on the positive strand, where inside is negative.

    (TIF)

    S2 Fig. Conditional essentiality of lambda ral in presence of an active type I restriction-modification system encoded by hsdR-hsdM-hsdS genes.

    (a) EOP experiments with crRNA targeting ral in E. coli BW25113 (methods). (b) EOP experiments with crRNA targeting ral in E. coli MG1655 that has an active type 1 restriction modification system. (c) EOP experiments with crRNA targeting ral in E. coli C3000 that has an active type 1 restriction modification system. For comparison, phage plaques appearing on E. coli lawn expressing a crRNA targeting essential gene P and nontargeting crRNA (targets P1 phage mcp) as a control are shown for lambda phage (Ctrl).

    (TIF)

    S3 Fig. CRISPRi of Nin region without and with plasmid expression gene Q: EOP experiments for assessing CRISPRi polarity effect on Nin region.

    (A) EOP for CRISPRi assay for each gene shown (each strain with individual CRISPRi plasmid (Methods). (B) EOP experiments in presence of plasmids pQ and CRISPRi targeting each gene in Nin region context. We used the BW25113 strain with a crRNA vector control (DP51, crRNA targets P1 phage mcp) for estimating EOP.

    (TIF)

    S4 Fig. P1 phage genome, CRISPRi oligo designs.

    Blue represents genes, red represents primers, and black is the full genome. Outside is on the positive strand, where inside is negative.

    (TIF)

    S1 Table. List of bacterial strains and phages.

    (XLSX)

    S2 Table. List of primers used in this work.

    (XLSX)

    S3 Table. List of plasmids used in this work.

    (XLSX)

    S1 Text. Detailed discussion on phage CRISPRi results.

    (DOCX)

    S1 Data. The underlying data for all figures.

    (XLSX)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    All relevant data are within the paper and its Supporting Information files. The underlying data for all figures are provided in supporting information file S1 Data. The complete data from phage Barseq experiments are deposited here https://doi.org/10.6084/m9.figshare.22817084.


    Articles from PLOS Biology are provided here courtesy of PLOS

    RESOURCES